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                                 ABSTRACT 
 
A study on echocardiographic profile of patients with chronic obstructive 
pulmonary disease. 
S .Manoj kumar, K.Anupama Murthy, R.Karthikeyan, G.Rajendiran, P.Arun 
kumar 
 
Department of Respiratory medicine, Cardiology; PSG Hospitals, 
Coimbatore, Tamil Nadu, India 
 
• Background: 
Chronic obstructive pulmonary disease (COPD) is a systemic disease with 
various extrapulmonary manifestations. Cardiovascular disease is a major 
comorbidity in COPD and probably the most frequent and most important 
disease co existing with COPD. Echocardiography is one of the simplest and 
non invasive tool in assessing the cardiac status. 
• Aim of the Study: 
To evaluate the clinico-physiological characteristics of copd and correlate 
them with the echocardiographic findings and to identify the predictors of 
pulmonary hypertension in COPD patients.  
  
• Materials and methods: 
Forty COPD patients diagnosed by GOLD criteria who neither has other 
lung disease which alters spirometry nor has primary cardiac disease were 
recruited. They were  explained about the study and interviewed for socio 
demographic details. They were subjected for thorough clinical examination 
and followed by Echocardiography.  
• Results: 
The frequency of mild, moderate, severe and very severe COPD were 7.5%, 
42.5%, 37.5%, 12.5% respectively.Pulmonary hypertension(PH) defined as  
systolic pulmonary artery pressure (sPAP) > 30 mmHg was found in 
35%(n= 14) of study subjects. None of them had s PAP > 50 mmHg. PH 
was present in 26.7%, 35.3% and 60% of moderate, severe and very severe 
COPD patients. The occurrence of PH increased with severity of COPD. 
None of the patients had RV systolic dysfunction documented by TAPSE 
with mean of 1.96±0.134. RV Hypertrophy based on RV Thickness was 
present irrespective of PH with mean of 0.68±0.13. LV Diastolic 
Dysfunction was present in 35%(n=14) of study population. By multivariate 
logistic regression analysis, BMI showed significant correlation with PH( 
adjusted odd’s ratio of 0.76, 95% confidence interval  0.59 – 0.98, P’=0.04) 
Duration of disease, 6MWD, LVDD does not correlate with PH. 
• Conclusion: 
 Our study showed that prevalence of pulmonary hypertension increased 
with severity of COPD. Severe pulmonary hypertension was not observed in 
our study with stable COPD patients. Right ventricle hypertrophy and 
diastolic dysfunction of left ventricle were the other common findings in 
COPD patients. We found that patients with low BMI have 24% less chance 
for developing pulmonary hypertension. Since cardiovascular disease is the 
major cause of morbidity and mortality in COPD, it is essential to evaluate 
the cardiac status at the time of initial diagnosis. The overall survival and 
quality of life can be improved by addressing this comorbidity. 
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                                             INTRODUCTION 
  DEFINITION: 
                      Chronic obstructive pulmonary disease (COPD), a common 
preventable and treatable disease, is characterised by persistent airflow 
limitation that is usually progressive and associated with enhanced chronic 
inflammatory response in the airways and lung to noxious particles or gases. 
Exacerbations and comorbidities contribute to overall severity in individual 
patients1. 
                    Emphysema, a pathological term often used incorrectly to describe 
COPD. It specifies one of the structural abnormality(alveolar wall destruction) 
occurring in COPD and does not emphasis on the changes occurring in airways 
and pulmonary vasculature. 
                   Chronic bronchitis is a clinical diagnosis described as production of 
sputum for minimum of  three months in 2 successive years. The airflow 
limitation may follow or precede it, So spirometry can be normal. 
EPIDEMIOLOGY: 
                    The prevalence of COPD according to PLATINO (Latin American 
Project for the Investigation of Obstructive Lung Disease) study was  7.8% in 
Mexico , as high as 19.7% in Uruguay2.The prevalence of COPD estimated by 
BOLD(Burden of obstructive lung disease program) among non smokers were 3 
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% to 11%3. Death due to COPD was ranked to be fifth in 2002. In the next ten 
years, COPD deaths will increase by atleast one third. In 2030, the third major 
etiology for death worldwide will be COPD4.   
                      The reported prevalence rate from the asian countries were lower 
than  the western world. In twelve Asia Pacific countries, the study by Tan et al  
point to the contrary and noted  6.3 % of combined prevalance. The above 
mentioned prevalence  was two times higher than the total  prevalance of 3.8 % 
depicted by World Health organisation88. Several small surveys  based on 
unvalidated questionnaire-interviews depicted 2 %to 22 % of COPD prevalence 
among males and  1.2 % to 19 % COPD prevalence among females, which 
enormously varied in their methodology and could not be relied for  national 
assessment89.  INSEARCH - The Indian study on Epidemiology of Asthma, 
Respiratory symptoms and Chronic bronchitis was aided by the Indian Council 
of Medical Research (ICMR)  to study the epidemiology of chronic respiratory 
diseases. The first Phase of the study was done in four areas and the second 
phase was carried out in twelve places. The first phase results from Bangalore, 
Chandigarh, Kanpur, Delhi showed 5.0 % prevalence in males and  the female 
prevalence was 3.2 % 87. 
                       The burden of  COPD during 1971 was about 6.45 million. In 
2011 it  increased to 14.84 million. The rise in population is one of the 
important reason for such high burden.  Among Indians, COPD is high in men 
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and smokers. The increased male prevalence is because of male : female 
differences in smoking habits86,87.  The male : female COPD ratio and the 
smoker : nonsmoker ratio  are not as high as in the Westernpopulations86,87.  
This is due to increased exposure of fumes among females, especially in the 
rural and hilly areas, on combustion of wood for heating ,cooking90. In non 
smoking women, exposure to environmental tobacco smoke is a significant  risk 
factor. Certain geographical and regional difference exists in COPD occurence . 
Earlier, COPD was said to be more common in North India88.The  distribution 
of chronic obstructive pulmonary disease in each state has not been studied 
extensively. The INSEARCH data are from specific areas of various states. So, 
the prevalence in each state cannot be estimated from the above data. According 
to Health Resource Centre in Maharastra, major cause of mortality is COPD 91. 
                     Airway obstruction is an important cause of dyspnoea on exertion.  
It  gradually worsens to limit the routine activities and an important cause of  
work loss.  Among non-communicable diseases, loss of 3 % DALY is due to 
COPD92. Stable COPD may get worsened due to comorbidities like Bullae  and 
pneumothorax . Pulmonary thromboembolism, hyperuricaemia, hyperviscosity 
secondary to polycythemia and long standing  hypoxia are the other 
abnormalities in COPD  . The presenting symptom in thromboembolism vary  
depending upon the level of obstruction in the vessel. 
          In 1988, a residential survey carried out in rural areas, estimated  0.57 
million COPD deaths . According to this limited death statistics, among the 
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non-communicable diseases, the major cause of mortality is chronic obstructive 
pulmonary disease next to the deaths reported due to trauma. The survey  from 
varied resources in rural India (NFHSI I , II ; Mortality survey,  Registrar 
General of India’s yearly manual,  2001 Indian census, various field studies)  , 
point asthma, bronchitis as the major cause of mortality in  men and women93. 
The amount spent on smoking related materials was around Rs.1340 yearly, Rs. 
11454 as indirect losses annually, according to an ICMR study in 1998. The 
costs reflected 30 percentage of the individual’s  income as financial Burden94. 
RISK FACTORS:           
                        Evidence are not from cause effect relation, but from the 
epidemiological cross sectional studies . No study has included pre/perinatal 
period. Gene environment interaction plays a major role and  link in complex 
ways. Cigarette smoking is a well known risk factor for COPD. WHO report 
states that around 15 billion cigarettes are smoked daily throughout the world4 
.COPD was more common in males as a result of smoking pattern. Both in 
high-income countries due to tobacco use and in low-income countries due to 
indoor pollution (biomass for cooking and heating), the prevalence of disease 
among women is on the rise1.  Genetic factors like alpha one antitrypsin 
deficiency, low birth weight, occupational exposure to fumes, ageing, outdoor 
air pollution, poor socioeconomic status 5,6,7 are the other major risk factors.  
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GENETIC FACTORS: 
            Alpha 1 antitrypsin deficiency, mmp12, hedge hog, Alpha nicotinic 
choline receptor are the major genes linked with COPD. Pi ZZ - homozygosity 
for the Z allele, is associated with severe  α1-AT deficiency (less than 15 
percent of normal).  Its incidence is about 1 in 3000 people in united states and  
rare among Asians, African Americans. The Z allele of α1-AT shows  slower  
association with neutrophil elastase than the association of normal α1-AT . So 
the persons with  Pi Z phenotype have a deficient  α1-AT  protein and  less 
efficient α1-AT than normal α1-AT. Majority of individuals present with 
respiratory symptoms, some have evidence of liver disease  and  small 
percentage have  rare clinical manifestations such as panniculitis. Some cases 
are detected from screening for α1-AT deficiency prompted by finding the 
deficiency in a family member. Smoking is highly deleterious and hastens the 
development of  COPD in  most people with the deficiency. The typical 
Pi Z individual who smokes has respiratory symptoms by age 40, about 15 years 
earlier than equally deficient individuals who have never smoked. Some 
individuals with PiZ,  present with respiratory symptoms only in advanced age . 
AGE & GENDER: 
   Healthy aging as such leading to COPD  is unclear. It may be due to 
cumulative risk exposure. In developed nations,  prevalence almost equal in 
both sex. Women are more susceptible to the effects of smoke.  
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LUNG DEVELOPMENT: 
                   FEV1 in adulthood has positive correlation with birth weight. 
Recurrent childhood respiratory infections will have negative impact on lung 
function .Childhood disadvantage factors are as important as smoking . 
SOCIO ECONOMIC STATUS: 
                     People belonging to low socioeconomic status had documented to 
have reduced lung function than the high socioeconomic status. Malnutrition, 
indoor pollution, infection and over crowding were the proposed mechanism. 
TUBERCULOSIS AND HIV: 
                      Post Pulmonary tuberculosis changes like bronchiectasis, fibrotic 
changes of airway were also well known etiology for COPD. HIV infection  
accelerate smoking related emphysema. 
FAMILY HISTORY: 
                    Significant  airflow obstruction  has been documented in smoking 
siblings of COPD patients. Individuals with history of airway hyperreactivity 
and family history of asthma were at high risk of developing COPD. 
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DIAGNOSIS OF COPD: 
 A diagnosis of chronic obstructive pulmonary disease must be considered in an 
individual presenting with complaints of breathlessness on physical activity, 
cough which  is chronic and associated with expectoration of sputum , with 
background exposure to risk factors. The other symptoms like chest tightness, 
wheeze are non specific. In patients with severe, very severe obstruction 
symptoms like fatigue, anorexia which are regarded as co morbidities. Patients 
who developed corpulmonale have swelling of feet, abdominal distention and 
decreased urine output. Patient may have syncope secondary to cough. Rib 
fractures are not uncommon in COPD.  In advanced stages, clinical examination 
show the features of  hyperinflation of lungs like reduced breath sounds , 
diaphragm at low level, percussion revealing hyper resonant note and a distance 
of 4 cm or below when measured between thyroid and cricoid cartilages. 
Spirometry should be performed to establish the airflow obstruction. The post 
bronchodilator FEV1/FVC ratio lower than 0.70 documents the presence of 
airway obstruction.Based on GOLD criteria, they are classified as mild, 
moderate, severe, very severe disease based on post bronchodilator spirometric 
FEV1 >80%, FEV1 <80% to >50%, FEV1 <50%  to 30%, FEV1 <30% 
respectively. 
         The assessment of COPD should also include the severity of symptoms, 
especially dyspnoea, according to modified medical research council grade or 
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by using COPD Assessment Test questionnaire. The previous history of 
exacerbation or hospitalization should also be considered during assessment of 
COPD .Chest xray show hyperinflated  lung parenchyma, flat diaphragm, 
tubular heart, widened intercostal space. HRCT Thorax may show the 
emphysematous changes and in some patients bulla can be visualized. It helps 
to rule out the other coexisting diseases like interstitial lung disease, 
bronchiectasis. Lung volume measurements by helium dilution, body 
plethysmography, single breath method or nitrogen washout technique can help 
in determining residual volume and total lung capacity which cannot be 
measured by spirometry. Diffusion capacity by carbon monoxide inversely 
correlates with emphysema. 
Differential diagnosis of emphysema: 
1. Air trapping in acute asthma 
2. Obstructive hyperinflation 
3. Compensatory hyperinflation 
4. Congenital lobar hyperinflation 
5. Ductectasia 
6. Swyer James syndrome 
Differential diagnosis for lesion in large airways: 
1. Chronic bronchitis 
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2. Bronchiectasis 
3. Asthma 
4. Relapsing  polychondritis 
5. Tracheomegaly 
6. Tracheobronchiopathica osteoplastica 
Differential diagnosis for lesion in small airways of COPD: 
1. Asthma 
2. Constrictive bronchiolitis 
3. Follicular bronchiolitis 
4. Proliferative bronchiolitis 
5. Panbronchiolitis 
PROGNOSIS:  
Morbidity and mortality in COPD  are influenced by various factors. COPD 
patients with low Body mass index, low exercise capacity assessed by six 
minute walk test, decreased FEV1, low DLCO, comorbidities, recurrent 
exacerbations, poor health related quality of life, resting tachycardia, 
corpulmonale, hypoxemia, active smoking were shown to have poor prognosis. 
COPD patients with forced expiratory volume in first second value of less than 
35% of predicted  have a mortality of around  10% every year. According to 
BODE index, the two year mortality for a patient with score more than 7 is 
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30%, for those with a score 5-6 have a 15% mortality and patients with score 
less than 5 have a better prognosis with a predicted two year mortality of 10%. 
PREVENTION OF DISEASE PROGRESSION: 
                     COPD patients have  progressive decline in pulmonary function 
even  with treatment. This deterioration in pulmonary function is rapid in 
actively smoking patients. Smoking cessation helps to avoid the fast decline in 
lung function. Occupational exposure to fumes, irritant would alter the lung 
function. They are educated to use respiratory protective devices. COPD 
patients should be immunized with influenza vaccine every year. The 
progression can be halted in patients with COPD due to alpha 1 anti trypsin 
deficiency by administering alpha one anti trypsin extract derived from plasma 
of humans. A dose of 60 mg per week by intravenous administration is 
recommended. The benefit will be more for moderate COPD patients. To 
prevent the deconditioning of muscle, COPD patients are encouraged to 
undergo self directed physical activity. They should be motivated  to do aerobic 
low intensity physical activity for a minimum period of twenty minutes atleast 
thrice weekly. COPD patients who have breathlessness of grade 2 MMRC 
should be encouraged to participate in rehabilitation program .The importance 
of nutrition and nature of the disease state should be emphasized.   
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COPD AND SYSTEMIC MANIFESTATIONS: 
                 There are plenty of evidence indicating chronic obstructive 
pulmonary   disease  as a complex disease with various systemic manifestations. 
These systemic manifestations occur due to the release of cytokines like Tumor 
necrosis factor alpha, Interleukin 1β, chemokines, Interleukin 6; Acute phase 
reactants like Fibrinogen, C-Reactive Protein(CRP), Surfactant D, Serum 
Amyloid A; Circulating cells like lymphocytes, monocytes and natural killer 
cells10,11.  
                 The comorbidities linked with COPD are cardiovascular diseases, 
metabolic syndrome, osteoporosis, depression, lung malignancy, skeletal 
muscle dysfunction, normocytic anemia, obstructive sleep apnoea1(Table 1)   
The different views  relating Chronic obstructive pulmonary disease with its 
manifestation and comorbidities are  
1. Systemic manifestations occur as a result of ‘‘ direct spill over’’ of  the  
inflammatory pathways taking place in the lungs of  COPD patients. 
2. Systemic inflammation also occurs due to release of mediators like IL-6 
in tissue hypoxia, increased 1L -8, TNF α, IL - 1β in hyperinflation of 
lungs, muscle dysfunction, bone marrow stimulation. 
3. Increased oxidative stress due to reactive oxygen species(ROS) especially 
oxygen radicals. 
4. Aging with shortened telomere length is a cause for systemic 
inflammation as a result of release of 1L -6, TNF α by senescent cells. 
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5.  The pulmonary manifestations in  COPD are another form of expression 
of a systemic  inflammation with various organ compromise 8,9. 
Table- 1 Chronic obstructive pulmonary disease and Systemic 
manifestations. 
Coronary artery disease 
Arrhythmia 
Congestive cardiac failure 
Systemic hypertension 
Pulmonary hypertension 
Cerebrovascular disease 
Peripheral vascular disease 
Obstructive sleep apnoea 
Diabetes 
Metabolic syndrome 
Skeletal muscle wasting 
Lung cancer  
Anxiety 
Depression 
Osteoporosis 
Normocytic anaemia 
Cachexia 
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Figure 1.  Mechanism underlying the association between chronic 
obstructive pulmonary disease (COPD) and cardiovascular disease. 
 
   
CARDIOVASCULAR DISEASE: 
                         The lungs and the heart  have an anatomical and functional 
relation, any altered function in one of the organs will have an impact on the 
other. This is of paramount importance in COPD individuals which is explained 
by the following associations.  
1. Pathologies sharing similar risks - cigarette smoking is a common risk 
factor for disease in coronary artery (CAD), congestive cardiac 
failure(CCF), COPD. 
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2. Presence of minimal level of  systemic inflammation 
3. Physical inactivity 
4. Activation of sympathetic nervous system – high resting heart rate, 
reduced heart rate variability. 
5. Increased arterial stiffness measured by pulse wave velocity(PWV). 
6.  Altered cardiac function from primary pulmonary disease like secondary 
pulmonary hypertension , decreased ventricular function due to    
increased intra thoracic mechanical loads. 
 Cardiovascular disease is the most important comorbidity in COPD patients. 
The major cardiac manifestations are ischemic heart disease, cardiac failure, 
arrhythmia, systemic hypertension and pulmonary hypertension. In mild and 
moderate COPD, the major cause of mortality are the cardiac complications. 
 
COPD AND CORONARY ARTERY DISEASE: 
             COPD and CAD  have common risk factors like exposure to cigarette 
smoke, sedentary life style and old age. Patients with airflow obstruction were 
prone to death from myocardial infarction which is independent of smoking 
history, age, sex. The Lung Health Trial, followed 6,000 COPD patients for 14 
yrs, found  FEV1 as an independent factor for  predicting the probability of 
mortality from  myocardial infarction. The above risk persists even after 
allowing for smoking.  COPD patients with mild obstruction have a higher 
mortality from cardiac etiology than from pulmonary cause per se. The factors 
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linked with the COPD and atherosclerotic  disease  overlap each other . 
Mannino did a  population based study and showed individuals with very severe 
obstruction had a two fold greater risk of cardiovascular disease, higher risk of 
hospitalization  and a 1.6 times increased prevalence of hypertension74. The 
occurrence of minimal systemic inflammatory changes could be the possible 
event  driving both  COPD and atherosclerotic cardiovascular disease . The 
systemic inflammatory mediators in COPD has been proposed in the genesis of  
coronary heart disease and atherosclerosis. The increased amount of 
macrophages, Interferon secreting Th1 lymphocytes are present in peripheral 
lungs of COPD and atherosclerotic plaques. 
COPD AND HEART FAILURE: 
               The dynamic hyperinflation and  increased intra thoracic pressure 
swings auguments the mechanical load on cardiac chambers. Rutten found  left 
ventricular dysfunction of  20% among COPD patients75. The overlap in 
symptoms and signs complicate the diagnosis of heart failure in COPD. Cardiac 
failure in COPD patients can be differentiated by measuring B type natriuretic 
peptide, N terminal prohormone brain natriuretic peptide (NT-proBNP).  
NTproBNP when elevated  in COPD patients has been shown to correlate with 
decreased physical activity, suggesting that  left ventricular dysfunction 
contributes  exercise limitation. It is shown that if the heart dimension  is 
reduced in patients with emphysema,  the actual volume of 
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intra thoracic blood is also decreased. After lung volume reduction surgery,  
intra thoracic blood volume increases in patients with hyperinflation. 
This  improved left ventricular function after the alteration in intra thoracic 
pressures makes the concept of systemic  inflammation implicated in causing 
heart failure debatable. 
ARTERIAL STIFFNESS AND ENDOTHELIAL FUNCTION: 
                    Arterial stiffness, one of the  predictor of cardiovascular events can 
be computed noninvasively by  radial artery tonometry or calculating aortic 
pulse wave velocity. Stiffness of  artery is increased in COPD patients than the 
normal smokers and nonsmokers Arterial stiffness is neither related to severity 
of disease nor circulating amount of  C Reactive protein. This increased arterial 
stiffness  predispose  to high risk of cardiovascular disease and systemic 
hypertension. Arterial stiffness depict common pathological mechanisms like 
connective tissue abnormalities and systemic inflammation. The possible 
mechanism for decreased arterial stiffness is impaired release of endothelial 
nitric oxide. Patients having emphysema show decreased flow mediated 
vasodilatation reflecting impairment in function of endothelium due to systemic 
inflammatory markers.  
PULMONARY HYPERTENSION: 
                       Impaired endothelial function as a result of  endothelial injury by 
cigarette smoke products and decreased endothelial expression of  nitric oxide,  
prostacyclin synthase are being proposed as the initial mechanism in the natural 
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pathway of pulmonary hypertension in COPD12 .  During the course of disease, 
sustained hypoxemia and inflammation induce vascular remodeling13. 
                  Measuring pulmonary artery pressure by right heart catheterisation 
has been the gold standard technique. Due to invasive nature of the procedure 
and associated complications, it is not routinely performed. The estimate of 
pulmonary artery pressure by echocardiography has been shown to have good 
correlation to that of invasive measurement. Moreover echocardiography is non 
invasive tool, simple to perform, cost effective. It also helps to measure various 
parameters like ejection fraction, dimensions of chambers, valve functions. So, 
echocardiography can be used as a screening tool  in assessing the cardiac 
status. 
In mild and moderate COPD, clinically significant pulmonary hypertension at 
rest is rare but can develop during exercise. Very severe COPD patients 
undergoing  lung transplantation or lung volume reduction surgery  (LVRS)  
have been documented to have moderate to severe PHT in about 50% of cases 
15
.  There are group of COPD  patients( 1 to 3%) having  PHT disproportionate 
to the degree of airway obstruction 14. Thus varying prevalence of pulmonary 
hypertension had been demonstrated in different studies. Some studies included 
patients with exacerbation. COPD patients at the  time of exacerbation will have  
increased pulmonary pressure when compared to the stable nature of the 
disease. Pulmonary hypertension corpulmonale are independent risk factors in 
predicting morbidity, mortality in patients with chronic obstructive pulmonary 
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disease. The presence of severe pulmonary hypertension in patients with COPD, 
needs further work up to exclude coexisting disease. The presence of pulmonary 
hypertension in COPD patients had poor survival rate. The 5 year survival rate 
for mild , moderate and severe pulmonary hypertension were 50% , 30% and 0 
% respectively. Varying  prevalence has been shown for pulmonary 
hypertension in different studies. Echocardiography, a noninvasive tool  gives  
data about the presence of PH (increased tricuspid regurgitation, jet velocity and 
right ventricular dilation) and about structural abnormalities(intra cardiac shunts 
)28. 
      Hence it is warranted for all COPD patients to have cardiac assessment 
at the time of diagnosis and/or during stable nature of the disease especially 
after an exacerbation. 
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                                AIM OF  OUR STUDY 
 
 
Primary Aim: 
                To evaluate the clinico-physiological characteristics of COPD and 
correlate them with the echocardiographic findings. 
 
 
     Secondary Aim: 
            To identify the predictors of pulmonary hypertension in COPD patients.  
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                                    MATERIALS AND METHODS: 
 
Source of data: 
              Patients diagnosed as COPD based on spirometry in the department 
of Respiratory medicine, PSG Hospitals affiliated to PSG IMSR located at 
Coimbatore, Tamil  Nadu, India. 
 
Sample Size: 
            Forty Subjects. 
 
Study Duration: 
           May’ 2013 to May’ 2014.   
 
Study Design: 
          Prospective cross sectional 
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   INCLUSION CRITERIA:   
•  Age of onset of disease >40 years. 
• Patients with symptoms suggestive of copd. 
• Diagnosis of copd based on GOLD criteria. 
• Willing to participate in the study 
  
    EXCLUSION CRITERIA: 
• History suggestive of asthma. 
• Other lung diseases that significantly contribute to decline in lung 
function. 
• Patients with clinically evident  active pulmonary tuberculosis. 
• Patients with primary cardiac disease. 
• Patients who have poor echo window. 
• Ongoing or recent exacerbation of copd within 2 weeks prior to the 
enrollment in the study. 
• Coexisting conditions that are contraindications or render forced 
expiratory maneuver difficult to perform. 
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ANTHROPOMETRIC MEASUREMENTS: 
           Weight and height are measured according to WHO  
recommended  procedure. 
 
Measurement of weight: 
            The weight of the study subjects were measured using the 
conventional standard weighing scale(Digital SECA Weighing scale, 
Model 753 E). With light clothing and without any foot wear, subjects 
were asked to stand on the platform of the weighing scale with 
bodyweight evenly distributed between both feet and weight was 
measured to nearest 0.1 kg. 
 
Measurement of Height: 
         The height was measured using the stadiometer. The subjects were 
asked to stand  in  erect position without foot wear. They were asked to 
put their feet together and stretch upwards to the fullest extent with the 
arms hanging on the side. The height was measured to nearest 1 cm. 
 
 EVALUATION PLAN: 
                Patients  diagnosed as COPD were screened for 
inclusion/exclusion criteria. The eligible subjects were explained 
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about the study and those willing to participate were enrolled.  After 
getting written consent,  they were interviewed for socio demographic 
details, medical history and  subjected for thorough clinical 
examination. Based on GOLD criteria are classified as mild, moderate, 
severe, very severe disease based on post bronchodilator spirometric 
FEV1 >80%, FEV1 <80% to >50%, FEV1 <50%  to 30%, FEV1 
<30% respectively(Table 2). Six Minute Walk Test was done 
according to American Thoracic Society(ATS) recommendations. 
Echocardiography was done according to the guidelines by American 
Society of Echocardiography followed by cardiologist opinion was 
obtained. 
 
DATA ANALYSIS  
Statistical analysis was carried out using SPSS version.17 software. 
For continuous variables, mean, standard deviation  were calculated 
and independent ‘T’ test was used for comparison. Categorical 
variables were expressed in percentage and Chi –square test was used 
for comparison. Statistically significant variables were subjected to 
multiple logistic regression. 
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Table.2: GOLD classification of COPD based on airflow limitation  
                   
                       GRADE 
 
POST BRONCHODILATOR FEV1 in 
COPD patients having 
       FEV1/FVC less than 0.7 
I- MILD COPD 
 
FEV 1 ≥ 80% of predicted 
II- MODERATE COPD 
 
50% ≤ FEV1 less than 80% of 
predicted 
III- SEVERE COPD 
 
30% ≤ FEV1 less than 50% of 
predicted 
IV- VERY SEVERE COPD 
 
FEV 1  less than 30% of  predicted 
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FLOW DIAGRAM OF STUDY DESIGN: 
Patients who have been diagnosed as COPD by GOLD criteria will be 
screened for inclusion/exclusion criteria. 
  
Eligible candidates are explained about the study. Written informed consent is 
obtained from all eligible subjects who are willing to participate in the study. 
         
Enrolled subjects will be interviewed for sociodemographic details. 
                                                                                                 
They will be subjected to thorough clinical examination. 
 
Echocardiography will be done to the above patients and cardiologist opinion 
will be obtained. 
 
All collected data by above methods will be appropriately entered in case record 
form and analysed. 
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                                   REVIEW OF LITERATURE: 
 
HISTORY OF COPD: 
              Charles Fletcher 16,17  in 1977 described COPD as two entities, the one 
with chronic airflow limitation and the other with mucus hypersecretion. 
Fletcher and Peto postulated that the decline in FEV1 in susceptible smokers is 
more compared to non smokers and few smokers. Smoking cessation in 
susceptible smokers will prevent the rapid decline in FEV1. 
            SANCHEZ-SALCEDO et al.18 in their study with 103 younger and 463 
older patients for  2 years  found that (59%) of the younger patients were 
‘‘active smokers’’ compared with only 20% of the older group. Those who 
continues to smoke had rapid decline in lung function. 
        The Framingham cohort showed less decline in women who continued to 
smoke compared with men (23.9 versus 38.2 mL per year), and fewer female 
smokers  developed airflow obstruction (24.2%) than male smokers (33.0%)19 . 
         Emphysema is derived from Greek terminology which mean ‘ to 
blow into’, so “air-containing” or “inflated.” In 1679, Bonet described it as 
“voluminous lungs” and Morgagni in 1769 called it as  turgid because of air. 
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The enlarged airspace in emphysema was described by Ruysh in 1721. Mathew 
Bailie in 1807 clearly recognized the destructive character of emphysema. 
 
Laennec differentiated interstitial emphysema from emphysema proper and  
illustrated  increased collateral ventilation, air trapping  as  features of 
emphysema. He showed the  peripheral airways as  the primary site of 
pathology  in emphysema and enlarged airspaces can also occur with increasing 
age. Laennec described the association of emphysema with chronic bronchitis. 
In 1952,  J. Gough showed the anatomy of pulmonary emphysema by paper 
mount technique.  He  illustrated centrilobular emphysema then distinguished it 
from panacinar emphysema. The microscopic illustration of emphysema was 
given by McLean. He demonstrated the relation of destructive alteration  to 
inflammatory changes in bronchioles with changes in the vessels. 
                  Ciba Guest Symposia (1959) denoted emphysema  as “a condition of 
the lung characterized by increase beyond the normal of airspaces, distal to the 
terminal bronchiole, either from dilatation or from destruction of their walls”.  
Emphysema according to National Institutes of Health committee   - “ when 
there was  non uniformity in the pattern of  respiratory airspace enlargement,  
and orderly appearance of the acinus and  its components are disturbed”.  The  
emphysema was considered as a part of airspace enlargement. The term was 
applicable to  air space dilatation  beyond  the terminal bronchioles,  existing 
with /without fibrosis or destruction. 
 28 
 
 
Figure. 2.  Lung Health Study showing changes in spirometry. Intermittent 
quitters (–––) , continuous smokers(–––) and sustained quitters  
 
 
              COPD phenotypes were described based on  natural history and 
response to therapy20. They are 
1. The frequent exacerbator;  
2. The overlapping COPD/asthma patient 
3. The emphysema-hyperinflation patient. 
 
Recently due to increased use of HRCT Thorax in evaluating patients has 
led to description of two more phenotypes of COPD. 
1. COPD with bronchiectasis  
2. CPFE- Combined pulmonary fibrosis and emphysema21 . 
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  Chronic obstructive pulmonary disease (COPD)  causes  pathological change 
in four various lung compartments - central and  peripheral airways, 
parenchyma , pulmonary vasculature, varying  among  individuals. Bullae is as 
an emphysematous space  more than 1 cm in diameter. The classification of 
emphysema is based on the involvement of acini. The four recognized patterns 
are centriacinar, panacinar, paraseptal and irregular emphysema. In panacinar 
emphysema, the acinus  will be almost uniformly involved; When the  proximal 
portion of  acinus   is predominantly affected  then it is called as  proximal 
acinar emphysema(centrilobular emphysema). The destruction of  the distal part 
(alveolar sacs and ducts)  with relative sparing of the proximal portion, then it is 
distal acinar emphysema or  paraseptal emphysema .The  irregular involvement 
of acinus is termed asirregular emphysema or paracicatricial 
emphysema.(Figure 3).The centriacinar and panlobular emphysema were 
common compared to other types. 
               The physiological alterations in COPD are increased mucus secretion, 
ciliary impairment, airflow obstruction and hyperinflation , altered exchange of 
gases, pulmonary hypertension,  systemic effects. 
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Figure. 3. Anatomic changes of emphysema.  A. Centriacinar .  B . Distal 
acinar.  C .Panacinar .  D. Irregular (scar). Image courtesy- Fishman’s 
pulmonary diseases and disorders. 
 
 
.Pulmonary vasculature 
            The changes in pulmonary vasculature begins early during the course of 
the disease 22.The wall of the vessel thickens and therefore endothelial 
dysfunction  occurs23. Smooth muscle of the vessel enlarge followed by 
infiltration in the wall of blood vessels 24. During advanced stages of COPD, 
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deposition of collagen along with emphysematous destruction of the capillary 
bed  lead to pulmonary hypertension 25. 
 
Figure 4 .Pulmonary muscular artery of  a  COPD  patient – Thickened 
intima with narrowed lumen 
 
a) Immunostaining  - more intimal  smooth muscle cells. 
 b) Orcein stain -  Increased elastic fibre  deposits  in  intima 
 
Pulmonary Hypertension: 
             Pulmonary hypertension is defined as an increase of the mean 
Pulmonary artery pressure >25 mmHg at rest measured during right heart 
Catheterization 26.  To define  Pulmonary Arterial hypertension( PAH) the 
patient should also have documented  pulmonary wedge capillary pressure less 
than 15 mmHg. 
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Diagnosis of PHT: 
 PH is often a multifactorial disease. The diagnosis of PH should be stepwise, 
to confirm the existence of the disease and to identify the cause.(Figure 5) 
 
Table 3. Clinical classification of pulmonary hypertension 
1 . PAH 
       a. Idiopathic PAH 
       b. Heritable PAH( BMPR2) 
2. PH secondary to left heart disease 
3. PH secondary to lung disease and/or hypoxia 
     a. Chronic obstructive pulmonary disease 
     b. Interstitial lung disease 
     c. Sleep disordered breathing 
     d. Developmental lung diseases 
     e. Other pulmonary diseases with mixed restrictive and obstructive pattern 
     f. Alveolar hypoventilation disorder 
     g. Chronic exposure to high altitude    
4. CTEPH 
5. PH with unclear multifactorial mechanisms 
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Figure 5. Approach to a patient with Pulmonary hypertension 
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ECG: 
  Classical changes are  hypertrophy  and strain of right ventricle. 
Hypertrophied right ventricle and  deviation towards right axis are found in 87% 
and 79% of patients  respectively 27 
Right heart catheterization: 
               It helps to confirm the severity of the PH, check for vasoreactivity and  
 to  perform pulmonary angiography. The variables  recorded are cardiac output, 
right atrial and ventricular pressure, PAP and pulmonary artery occlusion 
pressure (wedge pressure)29. Vasoreactivity test helps to identify candidates 
who will be benefited by calcium channel blockers. The test is said to be 
positive  when mean PAP is less than 40 mmHg with a rise or no change in  
output. 
Echocardiography: 
Echocardiography, a noninvasive tool  gives  data about the presence of PH 
(increased tricuspid regurgitation, jet velocity and right ventricular dilation) and 
about structural abnormalities(intra cardiac shunts )28 
Estimate of Pulmonary artery pressure: 
                 Systolic pulmonary artery pressure (sPAP) is assumed equal  to right 
ventricular  systolic pressure(RVSP) in the absence of  stenosis in pulmonary 
valve or outflow tract obstruction. RV systolic pressure can be determined by 
addition of right atrial (RA) pressure (RAP) to the pressure gradient between the 
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right chambers . The pressure gradient between the right chambers can be 
calculated using the modified Bernoulli equation: 
            ∆P =  4  x  v2;  v is the tricuspid regurgitant velocity (TRv) 33,34,35,36. 
                     McQuillan BM et al 37 illustrated that TRv > 2.8 m/s  is a 
reasonable cutoff  to define elevated pulmonary pressures corresponding to a 
right atrioventricular pressure gradient > 31 mm Hg(figure 7), except in elderly 
and obese  patients.  Tramarin R et al, showed the ability to determine  tricuspid  
jet in COPD patients  is  lower than  in non COPD group with a range from  
24% to 77% 38,39,40 
  
Figure 6.  Assessment of right ventricle during opening of pulmonary valve. 
Transpulmonary  flow (top) and Regurgitation in tricuspid valve (bottom).  
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        The major concern during  evaluation of  sPAP  by echocardiography  is 
the risk of  underestimation of sPAP. This is probably due to the frequent 
underestimation of RAP  and TRv. False negative results can be minimized by 
measuring TRv  in multiple views, by using color flow Doppler with or without 
contrast41,42. 
           Kircher BJ et al 43 demonstrated the  non invasive estimation of RAP by 
measuring the size of inferior venacava  during  respiration. For visualising 
IVC, the patient should be in supine position and  in the subcostal view . The 
diameter should be measured at end-expiration  and at end-inspiration within 2 
cm of the right atrium 
Figure 7 .IVC visualized in the subcostal view. 
       Left – IVC normal diameter.                       Right – IVC dilated 
 
Pulmonary hypertension in COPD: 
         Elwing J et al 30 in their study of Pulmonary hypertension in COPD 
patients showed 10%-30% of patients with moderate to severe obstruction have 
elevated pulmonary pressures. Majority of PH in  COPD is of mild to moderate 
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type and severe PH occurs in less than 5% of patients. Oswald-Mammosser M 
et al 31 showed that COPD  associated with PH have both increased mortality 
and morbidity with a 5-year survival of 20% to 36 even in the era of long-term 
oxygen therapy. A  cohort study of COPD patients by Thabut G et al 32  who 
had undergone Lung volume reduction surgery, 50%  had mean PA pressure  
above 25 mm Hg. (Figure 8). 
 
 
 
 
 
 
Figure 8 . Distribution of Pulmonary artery pressure 
 
                 N.K.GUPTA et al evaluated 40 COPD patients with 
echocardiography and found high prevalance of PH, cor pulmonale, left 
ventricular dysfunction among more severe COPD 44. M.A.HIGHAM et al45 
analysed the utility of echocardiography in assessment of pulmonary 
hypertension secondary to COPD at imperial college school of medicine, 
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london among 70 COPD patients and showed significant correlation of 
TTPG(transtricuspid pressure gradient) with FEV1 of r=-0.26,p=0.05.                
B SHRESTHA et al did echo for 507 COPD patients who attended nepal 
medical college teaching hospital , Attarkhel and showed that 49.1% had mild 
PAH and 56.3% had features of corpulmonale 46. 
ANDREW C. STONE  et al 47 subjected 43 COPD patients for echo. 23 
patients had PAH( RVSP >45mmHg), of which 16 died during 1-year follow up 
compared with 5 of 20 patients with no PAH. They showed that  presence of  
pulmonary hypertension is correlated  with increased mortality in patients 
admitted with COPD.  Sultan et al57 found  Tricuspid regurgitation  jet  in 
70.9% of patients diagnosed  with COPD. Increased pulmonary artery systolic 
pressure was noted  in 51% of patients with TR (36% of total patients) 
Burgess et al noted TR in 68% of patients with COPD61.Gupta et al44 
found TR in 67.5% of study population and significant pulmonary hypertension 
was shown to be present in 63%. 
   Chatila et al found a 30% prevalence of pulmonary hypertension among 
the stable COPD63. Similarly 30 % and  40% prevalence of pulmonary 
hypertension was reported by Falk et al and Chaouat et al respectively64,65. 
Matsuyama et al66 have found elevated pulmonary artery systolic pressure 
in 32.8% of patients with COPD. Weitzenblum et al found pulmonary 
hypertension in 35% of patients with COPD measured invasively67. Burgess et 
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al68 have found elevated pulmonary systolic pressure in 34.4% of COPD 
patients.                    
A recent small cohort reported that the frequencies of PH in mild, 
moderate, severe, and very severe COPD were 16.67 %, 54.55 %, 60.00 %, and 
83.33 %, respectively44. In another study, the frequency of PH was also found to 
be 25 %, 43 %, and 68 % in mild, moderate, and severe COPD, respectively62 . 
Fayngersh V et al  studied the prevalence of PH in 105 stable COPD patient and 
found 60% (n=63) of patients with pulmonary hypertension. In their study, there 
was a significant association between FEV1 and pulmonary hypertension. 
COPD patients with PH had lower FEV1% predicted than the patients without 
pulmonary hypertension(51.8 ± 18.8 vs. 62.7 ± 20.5%, P = 0.006)69 
  In 2002, Scharf et al70 studied the hemodynamic characterization in 
patients with emphysema. They showed that COPD patients with pulmonary 
hypertension had lower FEV1  compared to those without FEV1 which was 
statistically significant. Mammosser et al31 in their study  on COPD patients to 
assess pulmonary hypertension enlightened that subjects with pulmonary 
hypertension had lower FEV1 than those without pulmonary hypertension. 
Bishop et al71 used different non invasive techniques in predicting pulmonary 
artery pressure including echocardiography and found no correlation between 
severity of COPD and pulmonary hypertension. 
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Left Ventricular Diastolic Dysfunction(LVDD) in COPD: 
Abroug F et al 48 in their study found 32% of patients  with LVDD during 
COPD exacerbation. Caram et al from their  study with 25 mild/moderate 
COPD and 25 severe/very severe COPD patient  found  mild  left diastolic 
dysfunction  among  88% of patients irrespective of COPD severity 
49
.Boussuges et al. found a  prevalence of 76% vs. 35% of  LVDD in COPD 
patients compared  to controls 50. Rutten et al. and Funk et al. reported a 
prevalence of 50% LVDD in their study 51,52.  Freixa et al. found a lower 
frequency of  LVDD (12%) in COPD patients 53. Schoos et al  found LVDD  in  
66% of  COPD patients . They showed that LVDD was not significantly 
associated with exercise capacity  (P = 0.278) 73.  Left diastolic dysfunction can 
be asymptomatic or manifest with classical heart failure symptoms. Diastolic 
heart failure is common in older age group, Hypertension , Diabetes Mellitus, 
cardiac ischemia and obesity 5. Fayngersh et al69 evaluated  the etiology and 
distribution of pulmonary hypertension in stable COPD subjects by 
retrospective analysis. In the above study, 105 had adequate tricuspid 
regurgitant jet for measuring pulmonary pressure. They had a cut off of 36 
mmHg for defining pulmonary hypertension. They noted a prevalence of  60% 
(ie sixty patients out of 105 had pulmonary hypertension with a mean value of  
45 ± 6 mmHg. Patients with pulmonary hypertension had higher age   
(71.1 ± 11.8) when compared to those without increased pulmonary pressure 
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with a mean of  63.7 ± 10.2 year, which was statistically significant ,‘P ‘ value 
of  0.001. Patients with pulmonary hypertension had decreased predicted 
percentage forced expiratory volume in first second with 51.8 ± 18.8 as mean 
value than those without elevated pressure with P  value of  0.006). By 
Multivariate logistic regression these two variables withstood their significance.  
Lung function variables like residual volume and total lung capacity , 
demographic variables like BMI, gender,  pack years and smoking status did not 
correlate with pulmonary hypertension.  
Gologanu et al100  noticed a worse outcome for patients with pulmonary 
hypertension. They also had an increased frequency of  exacerbation,  an 
increase in the healthcare cost and a poor quality of life. Vasoconstriction of 
capillaries secondary to hypoxia, dysfunction of endothelium  were the 
proposed mechanism.  Unexplained hypoxemia and breathlessness which is not 
correlating with the decline in pulmonary function, the possibility of pulmonary 
hypertension should be considered. The development of  PH during exercise is 
an independent predictor for the development of pulmonary hypertension at rest 
. The cardiac consequences of  pulmonary hypertension on the right ventricle 
can br screened early by echocardiography. Systolic pressure of pulmonary 
artery has high negative predictive value, hence it helps to rule out significant 
pulmonary hypertension , avoiding  invasive catherisation. Catheterization of 
right heart is not readily available in all centres.  
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Ertan C et al101 analysed by echo the distensibility of pulmonary artery in 
patients with COPD. This was a prospective study comparing male patients 
having COPD with healthy controls. Fractional shortening of right pulmonary 
artery, stiffness of pulmonary vessels were studied. The study sample was 54 
COPD patients and the control group had 24 volunteers. The normal individuals 
had good pulmonary artery distensibility compared to patients with COPD.  
COPD had a mean of 13.3 ± 8.1while healthy population had a mean of   
27.6 ± 4.9 with ‘P’ value of less than  0.001. TAPSE had positive association 
with distensibility of pulmonary artery. The distensibility had inverse 
correlation with pressure in pulmonary artery. COPD patients had impaired 
stiffness of pulmonary vessels and had inverse association with disstensibility. 
Significant correlation  noted between  mean PAP and isovolumic acceleration 
of right ventricle.Thickness of right ventricular wall (p < 0.01). Impaired right 
ventricle and more thickened right ventricular wall  were found with mean PAP 
(18 ± 3 mm Hg) in  non PH group. 
Hoffmann et al102  studied whether remodeling of pulmonary vessels in  
pulmonary hypertension of COPD and  idiopathic pulmonary fibrosis had 
similar biomarkers.  They combined  entire genomic  microarrays with  profile 
of pulmonary artery microdissected  by laser capturing. Interaction of receptors 
at extracellular level and the retinol pathway were the predominant mechanism 
involved.  Immunohistochemical staining and polymerase chain reaction found 
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type 3 collagen,  von Willebrand factor , thrombospondin 2 were altered among 
the extracellular matrix pathway. Many genes are linked  in the metabolism of 
retinol and extracellular matrix path,  enabling discrimination of vascular 
changes in idiopathic pulmonary fibrosis and COPD. 
            Gokdeniz T et al103 evaluated  by means of  two dimensional speckle 
tracking echocardiography  among 135 COPD and 37 observation arm,  the 
relation between BODE index and function of right ventricle. Compared to 
observational arm, patients with  airflow obstruction had diastolic dysfunction.  
Functional parameters of right ventricle like TAPSE, strain of free wall 
fractional  change in area of right ventricle, TEI index had significant 
correlation with BODE index. Multivariate analysis showed strain of free wall 
as the significant variable. 
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SIX MINUTE WALK DISTANCE: 
In 1960, Balke inorder to evaluate the functional capacity developed a 
simple test, during which the distance walked in a defined time period was 
measured95. Cooper et al  for evaluating  the  physical fitness of healthy 
individuals developed a 12 minute field performance test 96. Mcgavin et al used 
walking test  to assess disability in patients with chronic bronchitis97. Butland 
found  walking 12 minutes was too exhausting for patients with respiratory 
disease, both six and twelve minute walk test performed equally98. Solway et al 
in their analysis on functional walking found that six minute walk test  is 
reflective of daily activities, better tolerated and easy to administer than the 
other walk tests99. 
  The test does not  require sophisticated equipments. Walking is a  daily 
performed activity. The distance covered over  a period of  six minutes are 
measured. The  integrated response of  the cardiovascular, pulmonary and other 
systems are evaluated. 
INDICATIONS : 
1. To compare pre and post treatment response 
               Lung resection  
               Lung transplantation 
               Lung volume reduction surgery  
               Pulmonary rehabilitation  
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               COPD  
               Pulmonary hypertension 
               Heart failure  
2. To assess functional status (single measurement) 
                COPD 
                Cystic fibrosis 
                Heart failure 
                Peripheral vascular disease 
                Fibromyalgia 
                 Older patients 
3. Predictor of morbidity and mortality 
                 Heart failure  
                 COPD  
                 Primary pulmonary hypertension  
 
CONTRAINDICATIONS: 
Absolute contraindications : 
1. Unstable angina during the previous month  
2.  Myocardial infarction during the previous month.  
 
Relative contraindications: 
1. Resting heart rate of more than 120,  
2. Systolic blood pressure of more than 180 mm Hg, and a diastolic blood 
            pressure of more than 100 mm Hg. 
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TECHNICAL ASPECTS: 
Location 
Indoors are always preferred for  6MWT  unless the outside weather is 
comfortable. The test is carried on a  lengthy,  flat and  straight with enclosed 
corridor having  a hard surface. The  corridor should  have 30 metres   length 
and  marked every 3 metres. The turning  areas are  marked with a traffic cone . 
The start  line and the end line are highlighted on the floor by  bright colored 
tape. 
Patient preparation 
Patients are advised  to 
1. Wear Comfortable clothing  
2.  Wear Appropriate shoes  
3. Use the routine walking aids at the time of  test ( walker). 
4.  Continue routine medications 
5.  Take a light meal  
6. Avoid vigorous exercise within 2 hours prior to  test. 
 
Factors influencing the test: 
 The test is negatively affected by 
1. Shorter height 
2. 2Older age 
3. Higher body weight 
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4. Female sex 
5. Impaired cognition 
6. A shorter corridor with more turns 
7. Musculoskeletal disorders (arthritis, lower limb injuries, muscle wasting.) 
The test is positively influenced by 
1. Taller height 
2. Male sex 
3. High motivation 
4.  Already performed  
5. Medication for a disabling disease taken just before the test 
6. Oxygen supplementation in patients with exercise-induced hypoxemia 
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SPIROMETRY 
 
 FEV1, FVC MANOEUVRE: 
      FVC is defined as the maximum amount of air exhaled with maximum  
effort after a maximal deep inspiration, i.e. vital capacity carried with a maximal 
forced expiratory effort and  expressed in litres at BTPS -body temperature and 
ambient pressure saturated with water vapour . 
     FEV1 is the maximum amount of air exhaled during the first second of a 
forced expiratory manoeuvre after a full inspiration, expressed in litres at BTPS. 
 
 BTPS correction: 
Spirometry values are reported at BTPS . For volume type spirometer, the 
temperature within the spirometer must be measured at every breath. The 
ambient temperature is documented with accuracy of  ± 1°C. When the  
temperature at ambient air changes quickly (more than 3°C in less than 30 min), 
sequential  temperature corrections are needed. Potential problem occur when 
the tests are performed at lower ambient temperature (17°C).  The barometric 
pressure  is  used to calculate BTPS correction factor. 
Requirement: 
           Spirometer with an accumulating volume for ≥15 seconds and with 
capacity of calculating volumes of   ≥8 Litres at BTPS with an accurate reading 
of at least ±3%  is recommended. The total airflow resistance at 14.0 L/s should  
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be  less than 1.5 cmH2O/ L/s  The total impedence  is calculated  with the tubes, 
valves and filter  included  between the subject and the spirometer. 
 
Procedure: 
 FVC manoeuvre has three phase 
 1. Maximum  inspiration 
 2. Blast of exhalation 
3. Continued complete exhalation to the end of test (EOT). 
 
            Spirometer calibration is checked. The subject is explained about the 
maneuver and  history of  smoking,  current  illness and treatment details should 
be documented. Weight, height are measured. Test should be demonstrated to 
the subject including exact posture with  slight elevated head , Position of the 
mouthpiece , rapid inhalation and complete exhalation  with maximal force. The 
tests are repeated for a minimum of three manoeuvres and maximum of  eight 
manoeuvres. 
 
Criteria for starting the test: 
                The exact timing  of the test during start  is determined by  back 
extrapolation method . For all timed measurements, the start is defined from 
back extrapolation  by the new ‘‘time zero’’. Manual  measurements can be 
done from  the volume–time curve by tracing back the  steepest slope  by the 
extrapolation method. The largest slope averaging above  80 millisecond  period 
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is recommended for computerized data. The EV  should  be  less than 5% of the 
FVC or 0.150 Litre for achieving  accurate time zero and to ensure that FEV1 is 
obtained from a maximal effort curve. An unnecessary prolonged effort can be 
avoided by terminating the test with an obvious hesitant start.  The volume-time 
curve must have the expiratory flow tracing, complete  prior  inspiratory tracing 
and should  include  time zero ( ≥ 0.25 second,  preferably  ≥1 second  prior to 
the beginning of exhalation). 
 
Criteria to end the test: 
            Subjects are motivated  to continue exhaling  the air at the end of the test 
to get optimal effort . Reasonable FVC effort can be identified by EOT criteria. 
 The recommended EOT criteria are 
 
1) If  the subject has  discomfort ,further exhalation should not be  
continued. 
2) The volume–time curve showing  no change in volume  ( less than 0.025 
Litre for  ≥1 second)  and the subject had exhaled for ≥ 3 seconds and for 
≥ 6 seconds,  in children less than 10 yrs and  adults more than10yrs 
respectively. 
 
Acceptability criteria: 
 A. Within manoeuvre ,  if Spirogram is free from 
       1. Artefact 
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       2. Cough during the first second of exhalation 
       3. Glottis closure that influences the measurement 
      4. Early termination or cut-off 
      5. Effort that is not maximal throughout 
      6. Leak 
      7. Obstructed mouthpiece 
 
If  Spirogram has 
1. good start 
2. Extrapolated volume  < 5% of FVC or 0.15 L 
3.  satisfactory exhalation 
4. duration of  ≥6 s (3 s for children) or a plateau in the volume–time curve  
 
B. Between manoeuvre : 
1. The two largest values of FVC must be within 0.150 L of each other 
2. The two largest values of FEV1 must be within 0.150 L of each other. 
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ECHOCARDIOGRAPHY: 
               In patients with Cardiopulmonary disease having significant clinical 
signs and symptoms , the right heart function plays an important role in 
morbidity and mortality. Right ventricle is not just a conduit of blood flow but 
also has prognostic significance in various clinical settings. It helps as a risk 
stratification factor, maintains  low systemic venous pressure to prevent 
congestion of tissues or organs , affects left ventricular  function by limiting LV 
preload in RV dysfunction due to ventricular interdependence. In patients with 
congestive heart failure and  associated  CAD,  poor  right ventricle ejection 
fraction has increased mortality. Inspite,  the right ventricular assessment  
technique varies within clinicians and the methods , assessment proves to be 
fragile because the importance is stressed over the left sided heart assessments. 
RIGHT  HEART  PARAMETERS : 
 Right ventricular (RV) size during systole and diastole 
Right atrial (RA) size 
RV systolic function  
              Fractional area change [FAC]   
              Tricuspid annular plane systolic excursion[TAPSE] 
               RV index of Myocardial performance [RIMP] 
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RV diastolic function 
Right ventricular wall thickness 
Systolic pulmonary artery  pressure  
Estimating  right atrial  pressure from  inferior vena cava (IVC) size ,collapse  
Pulmonary artery diastolic pressure(PADP)   
IMAGING WINDOWS AND VIEWS: 
                    The  assessment of  right ventricle systolic, diastolic function and 
right ventricle systolic pressure(RVSP) is made by the following views 
Left parasternal longaxis (PLAX)  
Subcostal view . 
 Apical 4-chamber 
 Modified apical 4-chamber 
Parasternal short-axis (PSAX) 
 
MEASUREMENT: 
RV DIMENSION: 
Right ventricle focused apical 4-chamber view is the best view to assess the 
right ventricular dimension. Crux and the apex should be focussed clearly to 
avoid foreshortening. RV enlargement is said to be present, when 
Basal diameter > 42 mm   
Midlevel diameter > 35 mm   
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The longitudinal dimension > 86 mm. 
RA DIMENSION: 
        The apical four chamber view  indicates the end diastole right atrial 
enlargement if   RA area  is more than 18 cm2,  
RA length( major dimension) > 53 mm, and  
RA diameter (minor dimension) > 44 mm . 
Right ventricle outflow tract dimension: 
              The left parasternal short axis view is the best view to assess the distal 
diameter at the level of pulmonary valves. The proximal portion is also assessed 
to evaluate the right ventricle outflow tract. Diameter > 27mm at end-diastole at 
the pulmonary valve attachment  indicates RVOT dilatation. 
Right ventricle wall thickness:  
RV wall thickness is measured  from the subcostal view during diastole, using 
either  two-dimensional  imaging or M mode. 
IVC DIMENSION: 
IVC is best seen through the subcostal view. It also helps to measure IVC 
and assess  collapse during inspiration. Diameter of inferior vena cava  is 
measured  proximal to the entrance of hepatic veins .Specific values  rather than 
ranges of  right atrial pressure must  be used in the estimation of  SPAP.IVC 
diameter  less than  2.1 cm that collapses  more than 50%  during sniff  indicates  
normal right atrial pressure of  3 mm Hg . IVC diameter  more than 2.1 cm that 
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collapses  less than  50%  during sniff indicateshigh right atrial  pressure of 15 
mm Hg . Young athletes and patients on ventilator commonly have dilated IVC. 
RV SYSTOLIC FUNCTION: 
                RV systolic function is assessed by parameters like TAPSE, RV FAC, 
RIMP,  2 D ejection fraction of RV,  three dimensional ejection fraction of RV, 
longitudinal strain , Tricuspid lateral annular systolic velocity  and strain rate.  
RV index of Myocardial performance : 
RIMP is an index of overall  right ventricle function.  The estimate of 
RIMP more than 0.40 by pulsed Doppler and  more than  0.55 by tissue Doppler 
suggest RV dysfunction. 
 TRICUSPID ANNULAR PLANE SYSTOLIC EXCURSION[TAPSE]: 
                  TAPSE  is a measure of   longitudinal function of right ventricle. 
TAPSE less than 16 mm indicates  systolic dysfunction of right ventricle.  It is 
calculated from the tricuspid lateral annulus. It correlates with the values 
recorded by methods  like  radionuclide derived  right ventricle ejection 
fraction.  
FRACTIONAL AREA CHANGE [FAC]: 
Two dimensional FAC  in  percentage  gives an estimate of  systolic 
function of right ventricle. Two dimensional FAC  below  35%  indicates right 
ventricle  systolic dysfunction.  
 
 56 
 
RV DIASTOLIC FUNCTION: 
       Right ventricle diastolic function can be assessed from tricuspid inflow by 
using pulsed doppler, from  lateral tricuspid annulus , by imaging hepatic vein 
with doppler, and  by measuring  size and collapsibility of inferior vena cava. 
The parameters like deceleration time , E/A ratio, the E/E´ ratio are also used to 
measure the RV diastolic dysfunction. 
GRADING OF DIASTOLIC DYSFUNCTION: 
Impaired relaxation when  tricuspid E/A ratio below  0.8   
 Pseudonormal filling when tricuspid E/A ratio of  0.8 to 2.1  and   
 Restrictive filling, if tricuspid E/A ratio  more than  2.1 
PULMONARY ARTERY SYSTOLIC PRESSURE:  
With the assumption of  no significant RVOT obstruction, TR velocity is 
made out which permits the estimation of RVSP..  The estimated right atrial 
pressure from size of inferior vena cava  and its collapsibility is added . 
Tricuspid regurgitant velocity more than 2.8 to 2.9 m/s, corresponds to around 
36 mmHg of systolic pulmonary artery pressure, assuming an RA pressure of 3 
to 5mmHg, indicating raised  pulmonary artery pressure. It varies with age , 
obesity status and should be correlated with the left heart findings. 
PULMONARY ARTERY DIASTOLIC PRESSURE:  
              PADP is calculated from the end diastolic pulmonary regurgitant jet 
velocity by applying  modified Bernoulli equation  
PADP = 4 x (end diastolic velocity of pulmonary regurgitation)2 + RA pressure. 
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The mean pulmonary artery pressure is estimated from the systolic and 
diastolic pressure by using the following  formula 
            Mean Pulmonary artery  pressure = 1/3(SPAP)+ 2/3(PADP). 
It must be measured  along with  mean arterial pressure or systemic blood 
pressure. Invasive PVR  measurement of   less than 1.5Wood units (120 dynes . 
cm/s2) is normal. In clinical studies, significant pulmonary hypertension is 
defined as PVR of more than 3 Wood units (240 dynes . cm/s2). 
Peak systolic velocity (PSV): 
PSV < 11.5 cm/s identifies the presence of RV dysfunction with 
Sensitivity of 90%, specificity of 85%. It is less affected by HR, loading 
condition, and degree of TR  
           As echocardiography is the initial test used in the evaluation of 
symptomatic cardiovascular patients, the assessment of right heart structure and 
function along with left heart parameters proves mandatory. 
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 RESULTS 
 
  We present our study results under the following description 
1. Distribution of study variables 
2. Comparison between physiologic variables 
3. Correlation of variables between PH and non PH group 
            
1. DISTRIBUTION OF STUDY VARIABLES: 
    Forty subjects were recruited in our study. All the participants were 
males (100%). The age of patients ranged from 40 to 80 years with a mean of  
60.65 ± 9.42 years. Based on their current occupational status, 28( 70%) 
subjects  were currently employed and 12(30%) of study subjects were 
unemployed. Twenty five(62.5%) subjects were urban dwellers while 
15(37.5%) subjects resided in rural area. All the forty of our study subjects 
consumed mixed diet.   (Table 4). 
.   Dyspnoea severity was enquired according to MMRC scale. 
Sixteen(40%) of subjects had grade 1 dyspnoea, while grade 2 and grade 3 
dyspnoea were reported by 20(50 %) and 4(10%) subjects  respectively. None 
of them had grade 4 dyspnoea. In the previous year, 25( 62.5%) subjects had 
atleast one exacerbation of their disease (Table 5). 
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Table.4: Socio demographic characteristics of the study population  
S.No Variable  Sample(n = 40) subjects 
1. Age (in years)  60.65±9.42 
2. Male gender (%) 40(100%) 
3. BMI (in Kg/m2) 21.44±3.49 
4. Socioeconomic status 
                          Class 1 
                          Class 2 
                          Class 3 
                          Class 4 
                          Class 5 
 
5(12.5 %) 
22(55%) 
9(22.5%) 
3(7.5%) 
1(2.5%) 
5. Diet 
                          Vegetarian 
                           Mixed 
 
0 
40(100%) 
6. Dwelling  
                           Urban 
                           Rural 
 
25(62.5%) 
15(37.5%) 
7. Current occupation status 
                           Employed 
                         Unemployed 
 
 
28(70%) 
12(30%) 
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BODY MASS INDEX: 
The mean BMI of the study group was 21.44 ± 3.49 Kg/m2. Twenty 
six(65%) subjects  had normal BMI. Underweight was present in 8(20%) of  
subjects. Overweight was documented in 7(17.5%) of subjects. None of our 
study population belonged to obese category. 
Figure 9.  Distribution of BMI. 
 
SOCIOECONOMIC STATUS:  
                        Socioeconomic status was assigned according to All India 
Consumer Price Index (AICPI) for industrial workers –May 2013 . Twenty 
two(55%) of our study subjects were in class 2. Nine(22.5%) subjects were in 
socioeconomic class 3. Five(12.5 %) subjects were in class 1, 3(7.5%) subjects 
in class 4 and only one subject in class 5. 
UNDERWEIGHT
NORMAL
OVERWEIGHT
OBESE
65%
15%
20%
OBESE 0%
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Figure 10  : Socio economic status of the study population 
 
 
SMOKING PATTERN: 
                                The mean smoking pack years of the study population was 
43.47 ±  24.16  pack years and 35(87.5%) subjects in our study had more than 
20 pack years while 15( 12.5%) subjects had less than 20 pack years (Table 2). 
 
DURATION OF DISEASE: 
                 The mean duration of symptoms among our study subjects was 5.8 ± 
3.5 years. Eighteen(45%) of them had symptoms more than 5 years and 
22(55%)  subjects had disease less than 5 years.(Table 2). 
 
 
CLASS1
CLASS2
CLASS3
CLASS4
CLASS555%
22.5%
7.5%
12.5%
2.5%
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Table. 5   Disease specific characteristics of study population 
S.No Variables Total subjects(n=40) 
1. Smoking  pack years 
                          More than 20 pack years 
                           Less than 20 pack years 
 
35(87.5%) 
5(12.5%) 
2. Duration of disease (in years) 5.8  ± 3.5 
3. Post bronchodilator FEV1 (in litres) 1.24  ± 0.49 
4. Post bronchodilator FVC (in litres) 2.25  ± 0.66 
5. Predicted FEV1 (in percent) 51.05  ± 16.09  
6. Spo2 (in percent) 97.25  ± 1.35  
7. 6MWD (in metres) 492  ±  90 
8. Dyspnoea –MMRC grade 
                                    Grade 1 
                                    Grade 2 
                                    Grade 3 
                                    Grade 4 
 
16(40%) 
20(50%) 
4(10%) 
0 
9. Co-morbidities 
                               No comorbidity 
                              Systemic hypertension 
                              Type 2 Diabetes  
                               GERD 
 
22(55%) 
4(10%) 
5(12.5%) 
4(10%) 
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COMORBIDITIES: 
                Comorbidities were present in 18(45% ) of subjects. Among the  
comorbidities, diabetes 5(12.5%) ,  hypertension 4(10%), Gastro Esophageal 
Reflux disease(GERD)  4(10%) were the commonest. In addition, both diabetes 
and hypertension were present in 3(7.5%) subjects. The other comorbidity noted 
in our study was Cerebro Vascular accident(CVA) in 4(10%) subjects. 
Figure 11.  Distribution of co morbidities 
 
 
0
5
10
15
20
25
NIL SHT SHT,DM DM CVA GERD
CO MORBIDITY
 64 
 
GRADING OF COPD BASED ON GOLD GUIDELINES : 
         The mean FEV1 among the COPD patients was 1.24 ± 0.49 litres  , the 
mean FEV1 % predicted was 51.05  ± 16.09 % and  the mean FVC was 2.25 ± 
0.66 litres. Three (7.5%) subjects had mild disease, Moderate obstruction was 
present in 17(42.5%) subjects, severe obstruction was noted in 15(37.5%) 
subjects, very severe COPD was diagnosed in 5 (12.5%) subjects . In our study 
32(80%) subjects had moderate to severe COPD (Table.3), (Figure.4). 
 
Table 6.   Distribution of the severity of COPD as per GOLD guidelines. 
 
GOLD grading of 
severity of COPD 
 
No of patients 
 
Percentage 
 
            Mild 
                   
                   3 
 
            7.5% 
 
         Moderate 
                    
                  17 
 
           42.5% 
 
         Severe 
                
                 15 
 
            37.5% 
 
       Very severe 
                   
                  5 
 
           12.5% 
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Figure 12. Distribution of the severity of COPD as per GOLD guidelines. 
 
 
2. COMPARISON BETWEEN PHYSIOLOGIC VARIABLES 
 
COMPARISON OF SEVERITY OF AIRWAY OBSTRUCTION WITH 
BMI. 
When severity of COPD were  compared with BMI, underweight was 
found in 3 patients of moderate COPD, 2 patients of severe COPD and 1 patient 
of very severe COPD. No underweight was found in mild COPD. Table 7  and 
Figure 5. 
 
Mild
Moderate
Severe
Very severe
37.5%
12.5%
7.5%
42.5%
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               Table 7.  Comparison of severity of  airway obstruction with BMI. 
Severity of COPD Underweight Normal Over weight 
Mild 0 3 0 
Moderate 3 9 5 
Severe 3 10 2 
Very severe 2 3 0 
         
 
             Figure 13.  Comparison of severity of airway obstruction with BMI. 
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COMPARISON OF SEVERITY OF COPD WITH DYSPNOEA GRADE: 
         Severity of dyspnoea was done by MMRC grading. Grade 3 dyspnoea 
was found in 50 % of very severe COPD patients. 18.8% of mild COPD, 
56.2% OF moderate COPD and 25% of severe COPD had grade 1 dyspnoea. 
Severity of dyspnoea showed significant correlation with severity of 
obstruction with P value of 0.023. 
 
Table 8 .Comparison between Severity of COPD and Dyspnoea grade 
MMRC Mild 
COPD 
Moderate                           
COPD 
Severe 
COPD 
Very Severe 
COPD 
Grade 1 18.8% 56.2 % 25% 0 
Grade 2 0 % 40% 45% 15% 
Grade 3 0% 0% 50% 50% 
( ‘P’ value = 0.023) 
 
SIX MINUTE WALK DISTANCE: 
                The mean distance covered during six minute walk test was 492  ± 90 
meters. Thirty seven(87%) subjects covered more than 350 meters. Only 
3(13%)  subjects walked less than 350 meters and they had  very severe COPD 
( ‘P’ Value = 0.001).   
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   Table 9. Comparing  severity of obstruction with 6MWD. 
Severity of COPD 6MWD < 350 meters 6MWD > 350 meters 
Mild 0 3 
Moderate 0 17 
Severe 0 15 
Very severe 3 2 
  P =0.001 
 
              Only 2(14%)vsubjects with pulmonary hypertension covered less than 
350 meters, where as 12(86%) subjects with PH walked more than 350meters.                                   
Table 10. Comparing six minute walk distance with pulmonary 
hypertension 
Distance covered in 6MWD Pulmonary hypertension (n = 14) 
Less than 350 meters 2(14%) 
More than 350 meters 12(86%) 
 P = 0.232 
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PULMONARY HYPERTENSION: 
  The  range of  pulmonary artery pressure was from 15mmHg to 
49mmHg. None of the patients had Systolic pulmonary artery pressure (s PAP) 
more than 50 mmHg. Pulmonary hypertension(PH) was found in 14(35%) of 
subjects.  Among patients with PH, 4(28%) subjects  had COPD symptoms for 
more than 5 years. Measurable tricuspid regurgitation(TR) was found in 
20(50%) of  our  study subjects. Among those with measurable TR, pulmonary 
hypertension defined by systolic pulmonary artery pressure was documented in 
14(70%)  subjects.  
   Table 11. Frequency of  pulmonary hypertension among COPD. 
 
Pulmonary 
hypertension 
 
No of subjects 
n = 40 
 
Percentage 
Present 14 35% 
Absent 26 65% 
       
                   The distribution of pulmonary hypertension among mild, moderate, 
severe and very severe COPD were 33.3%, 26.7%, 35.3% and 60% 
respectively( ‘P’= 0.607). 
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   Table 12 . Distribution of Pulmonary hypertension among study subjects. 
COPD severity No of patients with PH Percentage with PH 
Mild 1 33.3% 
Moderate 4 26.7% 
Severe 6 35.3% 
Very severe 3 60% 
 
  
 Figure 14 . Distribution of Pulmonary hypertension among study subjects. 
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      Figure 15.   Estimation of pulmonary artery pressure.     
 
 
  Figure 16.  Measurement of size of main pulmonary artery 
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     Figure 17.  Measurement of right and left pulmonary artery size. 
 
 
Table 13. Comparing duration of disease with pulmonary hypertension 
Duration of disease Subjects with PH 
Less than 5 years 10 
More than 5 years 4 
 
          (‘ P’ value = 0.125) 
    Heart valves: 
          Normal heart valves were found among 33(82.5%) subjects of our study 
population. The most frequent valve changes were age related sclerosis of aortic 
valve noted in 7(17.5%) subjects. 
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        Table 14. Distribution of valve status. 
 
       Valves 
 
   No of patients 
 
     Frequency 
 
         Normal 
 
            33 
 
           82.5% 
 
   Age related     
Aortic sclerosis 
 
             7 
 
            17.5% 
 
Right ventricle wall thickness(RVT): 
                      The mean RVT was 0.68 ± 0.13  cm. Twelve() subjects with PH  
had  RVT > 0.5cm and 2 subjects with PH  had  RVT < 0.5cm. The presence of 
pulmonary hypertension does not correlate with the thickening of right 
ventricular wall ‘(P’ value = 0.232). 
 
  Table 15.  Correlation of Right ventricle Thickness with pulmonary 
hypertension 
RVT Pulmonary hypertension (n =14) 
< 0.5 Cm                          2 
>0.5 Cm 12 
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Figure 18.   Comparison of Right ventricle Thickness with pulmonary 
hypertension 
 
 
 
Figure 19.  Measurement of Thickness and diameter of right ventricle 
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  Left ventricle Diastolic dysfunction(LVDD): 
                    LVDD was found in 14(35%) subjects of the study population. We 
studied  the distribution of LVDD among subjects in relation to severity of 
airway obstruction. LVDD was noted in 1(33.3%) of mild COPD, 4( 23.5%) of 
moderate COPD, 8(53.3%) of severe COPD and 1( 20%) of very severe COPD 
subjects. There was no significant correlation between the severity of COPD 
and  LVDD ( ‘P’ value of 0.296). 
 
      Table 16.   Comparison of severity of airway obstruction with LVDD  
Severity of obstruction Patients with LVDD 
Mild 33.3% 
Moderate 23.5 % 
Severe 53.3 % 
Very severe 20% 
  P = 0.296 
 
ECHO  FINDINGS AMONG STUDY POPULATION: 
The mean ejection fraction among the subjects was 62.27 ± 3.08 %.The 
diameter of left ventricle during systole and end diastole were normal with 
mean value of 2.7577 ± 0.2621 cm and 4.1508 ± 0.4336 cm respectively. 
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Figure  20. Measurement of E/A ratio to assess LV Diastolic function 
 
 
The diameter of right ventricle in all subjects were normal with  mean 
2.563 ± 0.46 cm. None of them had corpulmonale. Right ventricular 
hypertrophy defined by RV wall thickness was present in most of the study 
population with a mean value of 0.6842 ± 0.1344 cm. RV Systolic function  
assessed by TAPSE showed good right ventricular systolic function with mean 
of 1.9618 ± 0.2161 cm/sec. The  IVC diameter was measured by subcostal view 
and the mean diameter was 1.18 ± 0.23 cm. IVC collapsed well in all patients 
during inspiration. 
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Figure 21.  Measurement of  left  ventricle parameters 
 
 
Figure 22. Measurement of IVC size 
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 Table 17 . ECHOCARDIOGRAPHIC FINDINGS AMONG STUDY 
POPULATION. 
 
          
      S.No 
 
Parameter 
 
Mean ± SD 
 
 
1.  
 
Left ventricle internal diameter 
during systole (LVIDs) in cm 
 
 
2.75  ± 0.26 
 
2. 
 
Left ventricle internal diameter 
during diastole (LVIDd) in cm 
 
 
4.15  ± 0.43 
 
3. 
 
Right ventricle internal diameter in 
cm 
 
 
2.563  ± 0.46 
 
4. 
 
Tricuspid Annular plane Systolic 
excursion(TAPSE) in cm 
 
 
1.96  ± 0.21 
 
5. 
 
Right ventricle thickness in cm 
 
 
      0.68  ± 0.13 
 
6. 
 
Ejection fraction in percent 
 
 
      62.27  ± 3.08 
 
7. 
 
Interventricular septum in cm 
 
 
      1.25  ±  0.24 
 
8. 
 
Inferior vena cava in cm 
 
 
1.18  ±  0.23 
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 Figure 23.  Measurement of TAPSE 
 
3.CORRELATION OF VARIABLES BETWEEN PH AND NON PH 
GROUP 
               We divided the study population into two groups – PH group and non 
PH group and compared a set of variables like Age, BMI, Smoking pack years, 
duration of disease specific symptoms, lung function variables.  
                BMI and pack years were statistically significant between the two 
groups with a ‘P’ value of 0.030and 0.040 respectively. The subjects in PH 
group had lower BMI with mean of 19.8271 kg/m2 compared to the subjects in 
non PH with mean of 22.3115 kg/m2. The subjects in PH group had mean 
smoking  of 54.07 ± 28.09  pack years which was statistically significant when 
compared to the non PH group subjects with mean of 37.76  ± 20.09 pack 
years with ‘P’ value of 0.040.  The other variables like age, current 
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occupational status, co morbidities and duration of disease were not 
statistically significant between the two groups. 
 
Table 18. Sociodemographic and disease specific  variables among two 
groups. 
Variables PH group 
(mean ± SD) 
Non PH group 
(mean  ± SD) 
‘P’ value 
 
Age( in years) 
 
64.14  ± 9.07 
 
58.76  ± 9.23 
 
0.085 
 
BMI(in kg/m2) 
 
19.82  ± 2.59 
 
 22.31  ± 3.64 
 
0.030 
 
Smoking ( in Pack 
years) 
 
54.07  ± 28.09 
 
37.76  ± 20.09 
 
0.040 
 
Duration 
(In years) 
 
5.07  ± 3.09 
 
6.19  ± 3.78 
 
0.349 
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Comparison of disease specific variables: 
        In non PH group, 13( 81.2%) subjects had grade 1 dyspnoea while the 
PH group had 3(18.8%)  of  subjects. The severity of dyspnoea between the 
groups was not statistically significant. The co morbidity profile between the 
groups were compared and found that diabetes and systemic hypertension were 
the most common comorbidity in both groups, but the distribution was not 
significant. There was no comorbidity among 36% of subjects in PH group and 
it was 64% in non PH group. 
 
Table 19. Comparison of severity of dyspnoea among PH and non PH 
group 
MMRC PH group 
% of patients 
Non PH group 
(mean  ± SD) 
Grade 1 18.8%             81.2 % 
Grade 2 45%            55% 
Grade 3 50%             50% 
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Table 20. Comparison of  physiologic variables among PH and non PH 
group 
 
Variables 
 
PH group 
(mean ± SD) 
 
Non PH group 
(mean  ± SD) 
 
‘P’ value 
 
Post bronchodilator 
FVC(in litres) 
 
2.08  ± 0 .60 
 
2.34 ±0 .68 
 
0.233 
 
Post bronchodilator 
FEV1(in litres) 
 
1.15  ±  0. 51 
 
1.29  ± 0. .49 
 
0.393 
 
Post bronchodilator 
FEV1 (in percent) 
 
49.57  ± 16.75 
 
51.84  ± 16.01 
 
0.676 
 
6MWD(in metres) 
 
465.71  ± 84.28 
 
506.92  ± 91.37 
 
0.171 
 
Spo2 (in percent) 
 
97.07 ± 1.26 
 
97.34 ± 1.41 
 
0.547 
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Table 21. Comparison of  Echo variables among PH and non PH group 
 
Variables 
 
PH group 
(mean ± SD) 
 
Non PH group 
(mean  ± SD) 
 
‘P’ value 
TAPSE(in cm) 1.99  ± 0 .23 1.94  ± 0 .20 0.502 
RVT (in cm) 0.68  ±  0.16 0.68   ±  0.11 0.929 
RVID(in cm) 2.58  ± 0. .58 2.55  ±  0.39 0.863 
IVC(in cm) 1.21  ±  0.30 1.17  ±  0.19 0.599 
LVEI(in cm) 1.06 ± 0.10 1.08 ± 0.09 0.631 
EF(in percent) 64.07 ± 3.26 61.30 ± 2.55 0.005 
IVS(in cm) 1.29 ± 0.22        1.22  ± 0.26 0.400 
LVIDd(in cm) 4.14  ± 0.30 4.15  ± 0.49 0.928 
LVIDs(in cm) 2.69  ± 0.18 2.79  ± 0.29 0.251 
 
         There was no statistical significance between the PH and non PH group 
for the variables like FEV1, FEV1%, FVC, 6MWD, SPO2 and also for other 
echocardiographic variables except for ejection fraction.  
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Logistic regression analysis of variables between PH and non PH group: 
                    The significant variables like BMI, Smoking pack years were 
further analysed by using multiple logistic regression. Both BMI and smoking 
pack years were adjusted for Age, Duration of disease and  severity of COPD. 
Table 22  .Logistic regression analysis of variables between PH and non PH 
group: 
Variables Adjusted odds 
ratio 
95% confidence 
interval 
 ‘P’ Value 
BMI 0.76 0.59 – 0.98 0.04 
Smoking  pack 
years 
1.024 0.99 – 1.05 0.13 
 
               BMI remained statistically significant with ‘P’ value of 0.04( adjusted 
odd’s ratio of 0.76, 95% confidence interval  0.59 – 0.98). Smoking pack years 
lost its significance( ‘P’value of 0.13, adjusted odd’s ratio of 1.024, 95% 
confidence interval 0.99 – 1.05). We found that pulmonary hypertension was 
0.76 times commoner in patients with low body mass index. 
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                                                DISCUSSION 
      The important findings in our study were as follows 
1. The mean  post bronchodilator FEV1and predicted FEV1 in our study 
population were 1.24 ± 0.49 Litres and 51.05 ± 16.09% respectively. 
2. The prevalence of pulmonary hypertension increased with the severity of 
COPD. 
3. In stable COPD patients, the pulmonary hypertension were of mild grade. 
4. By univariate analysis, COPD patients with pulmonary hypertension had 
lower BMI and had high smoking pack years than the patients without 
pulmonary hypertension with ‘P’ value of 0.030 and 0.040 respectively.  
5. With Multiple logistic regression, BMI remained statistically significant 
with ‘P’ value of 0.04( adjusted odd’s ratio of 0.76, 95% confidence 
interval  0.59 to 0.98).  
                                 COPD is primarily characterized by the presence of airflow 
limitation . It is well known that COPD extends beyond the lung and has several 
systemic manifestations. These manifestations/Co morbidities further impair 
functional capacity and health-related quality of life. Cardiovascular disease is 
the most frequently recognized  co morbidity among COPD patients.The aim of 
our study was to evaluate the clinicophysiological characteristics of COPD and 
correlate them with the echocardiographic findings. The mean post 
bronchodilator FEV1and predicted FEV1 in our study population were 1.24 ± 
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0.49 Litres and 51.05 ± 16.09% respectively. We found 35%(n=14) of the stable 
COPD had mild pulmonary hypertension. None of the patient had severe 
pulmonary hypertension. The distribution of pulmonary hypertension among 
mild, moderate, severe and very severe COPD were 33.3%, 26.7%, 35.3% and 
60% respectively. Left ventricle Diastolic dysfunction(LVDD) was found in 
35% of the study population. Right ventricular free wall thickness more than 
0.5cm was found in 92.7%(n=37) of patients and none of them had features of 
corpulmonale. 
 
Sociodemographic characters: 
       In our study, 100 % of the subjects were males. Jindal SK et al and Buist 
AS et al86 reported COPD more in men than women because of the difference in 
smoking habits. Similarly both male:female  and smoker:non smoker ratios in 
india are not as high as in the western population, because of exposure to 
biomass fuels among women.The prevalence as per the INSEARCH 1 study 
(2006) which included 35,295 subjects  were  5% in males and 3.2% in 
females87. 
                          The  mean age of  patients in our study  was 60.65 ± 9.42 years. 
This was  similar to a study by Hilde et al with 98 COPD patients with mean 
age of 62  ± 8 years55.  In our study, 70% were currently employed and 32%  
were unemployed. The mean BMI of the study group was 21.44 ± 3.49 Kgs/m2. 
20% of patients had underweight. Low BMI  in COPD is an independent  risk 
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factor for increased mortality. Low BMI patients also have poor quality of life 
and increased risk of  exacerbation84. A study by Maurizio et al82 evaluated  
COPD  patients of  specific  phenotype D and  pulmonary hypertension, showed 
significant correlation between pulmonary hypertension and BMI.  Kadam et 
al84  in their study with 30 stable COPD patients showed that pulmonary 
hypertension had no correlation with BODE index. Socioeconomic status was 
assigned according to AICPI(IW) –May 2013 and  in our study major 
proportion(75%)  belonged to class 2 and class 3, while class 4 and class 5, in 
total had only 10%.  A study by Merja et al on asthma and COPD patients 
showed that basic educational level remained an independent risk factor for 
COPD and the low household income was a risk factor for asthma. Poor 
socioeconomic status is a well documented risk factor in COPD probably due to 
overcrowding and exposure to smoke1. Our study subjects had mean smoking 
pack years of  43.47 ±  24.16 pack years and 87.5%  had more than 20 pack 
years while 12.5% had less than 20 pack years. This result was almost similar to 
the study by Sultan et al , in which the mean pack years was 49.5 ± 22.2 pack- 
years57 . 
Physiological variables: 
                             The mean FEV1 among our study population was 1.243 ± 
0.49 litres , the mean FEV1 % predicted was 51.05  ± 16.09 % and  the mean 
FVC was 2.25 ± 0.66 litres. Three subjects (7.5%) had mild disease, Moderate 
obstruction was present in seventeen subjects (42.5%), severe obstruction was 
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noted in fifteen patients(37.5%), underlying very severe COPD was diagnosed 
in five subjects (12.5%) . In our study most of the patients(80%) had moderate 
to severe COPD. The mean six minute distance in our study was 492 ± 90 
meters. Schoos et al58 in their study titled Echocardiographic predictors of 
exercise capacity in COPD had recorded the distance walked during six minutes 
among 90 patients and the mean distance was 403 ± 113 meters. In our study, 
three patients walked less than 350 meters and all had very severe COPD. 
 
Jose M. Marin et al76, in 2001, showed  positive correlation between mean 
6MWDand  FVC, FEV1. Ameri et al79 found positive  correlation for six minute 
walk distance with diffusion capacity of carbon monoxide, Forced vital capacity 
and Forced expiratory volume in first second. Among them diffusion capacity 
correlated strongly with six minute walk distance,  followed by Forced vital 
capacity and FEV1. Safwat et al with thirty COPD patients  found strong 
association between predicted percentage of FEV1 and six minute walk distance 
with a ‘ r ‘ value of 0.77 and ‘p’ value  less than 0.01)77.  Nishiyama et al 
showed similar relation between six minute walk distance and spirometric 
values with  r = 0.70 and  P < 0.000178. Our study results showed significant 
correlation between six minute walk distance and FEV1 in concordance with 
the above studies. But a  study by Kodavala et al80  in 45 COPD patients to find 
the correlation  between 6MWD and severity of obstruction showed weak 
correlation ( r= 0.280), without statistical significance between six minute walk 
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distance to forced expiratory volume in first second with ‘p’ value of 0.062 and 
forced vital capacity with ‘ p’ value of  0.055. Six minute walk distance did not 
correlate with parameters like smoking score, BMI, age  and baseline arterial 
partial pressure of carbondioxide. Similarly, Elie Fiss et al81 found significant 
correlation was found between six minute walk distance and mean  predicted 
forced vital capacity percentage  and vital capacity but not for  Inspiratory 
capacity and FEV1. These  studies did not include patients with all grades of 
severity. 
Echocardiographic variables: 
    RV Systolic function  assessed by Tricuspid annular plane systolic 
excursion(TAPSE) showed good right ventricular systolic function with mean 
of 1.9618 ± 0.2161 cm/sec. There was no correlation between TAPSE and 
exercise capacity assessed by six minute walk distance. Our study finding was 
similar to the observation by Schoos et al , who showed TAPSE does not 
correlate with exercise capacity58. 
   LVDD in our study population was  35%.  LVDD was noted in 33.3% 
of mild COPD, 23.5% of moderate COPD, 53.3% of severe COPD and 20% of 
very severe COPD. There was no significant correlation between the severity of 
COPD and LVDD. Left ventricular diastolic dysfunction had been  documented 
in COPD with varying prevalence.  The right and left ventricle share a common 
interventricular septum(ventricular interdependence).The increase in LV end 
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diastolic pressure due to bulging of septum into left ventricle and increased 
afterload due to increase in intrathoracic pressure were the proposed 
mechanism44.  A study by Cuttica et al found 54% prevalence of LVDD in 
COPD patients. Schoos et al  found LVDD  in  66% of  COPD patients . They 
showed that LVDD was not significantly associated with exercise capacity  (P = 
0.278) 73. Abroug F et al 48 in their study found 32% of patients  with LVDD. 
Caram et al from their  study with 25 mild/moderate COPD and 25 severe/very 
severe COPD patient  found  mild  left diastolic dysfunction  among  88% of 
patients irrespective of COPD severity 49.Boussuges et al. found a  prevalence 
of 76% vs. 35% of  LVDD in COPD patients compared  to controls 50. The 
higher prevalence rate found in the above studies was possibly due to 
enrollment of patients during exacerbation. We had more stringent selection 
criteria excluding patients with exacerbation within two weeks prior to 
recruitment. This criteria ruled out any transient dynamics in cardiac function 
during exacerbations. 
  Right ventricular hypertrophy defined by RV wall thickness more than 
0.5 cm  was present in most(92.7%) of the study population with a mean value 
of 0.68 ± 0.13 cm and  prevalence of  right ventricular hypertrophy both  in 
pulmonary hypertension and non pulmonary hypertension group were  
comparable.  Hilde et al55 analysed  the structure and function of right heart in 
COPD patients with normal pulmonary artery pressure and found that patients 
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with Right ventricular hypertrophy were more in  the pulmonary hypertension 
group comparing the non  PH group.  
 
The measurable tricuspid regurgitation in our study population was found 
in 50% of the subjects. Among those with measurable TR, significant 
pulmonary hypertension was noted in 70% of subjects(35% of total subjects). In 
our study the distribution of pulmonary hypertension among mild, moderate, 
severe and very severe COPD were 33.3%, 26.7%, 35.3% and 60% 
respectively. Sultan et al57 found  Tricuspid regurgitation (TR) jet  in 70.9% of 
patients with COPD. Increased pulmonary artery systolic pressure was noted  in 
51% of patients with TR (36% of total patients). Burgess et al noted TR in 68% 
of patients with COPD61. Gupta et al44 found TR in 67.5% of study population 
and significant pulmonary hypertension was shown to be present in 63%.  
 
In our study, the prevalence of pulmonary hypertension was 35%. 
According to severity of COPD, three subjects (7.5%) had mild disease, 
Moderate obstruction was present in seventeen subjects (42.5%), severe 
obstruction was noted in fifteen patients(37.5%), underlying very severe COPD 
was diagnosed in five subjects (12.5%) . In our study most of the patients(80%) 
had moderate to severe COPD.  N.K.GUPTA et al 44 evaluated 40 COPD 
patients with echocardiography and found pulmonary hypertension among 63% 
(n=17). Among their 40 COPD subjects,  45% had  mild COPD, while 
moderate, severe and very severe COPD were 27.5% , 12.5% and 15% 
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respectively. A study by Higham et al on the utility of echocardiography  in 
assessing  pulmonary hypertension secondary to COPD showed a prevalence of 
55% among their study subjects. Their study  had 16% of mild COPD, 26% of 
moderate COPD and 57% of severe COPD The majority of subjects(83%) in 
their study had moderate to severe COPD.  Our study results were comparable 
to the study by Higham et al45. 
 
The pulmonary pressure in COPD patients had shown to increase 0.4 to 
0.6mm Hg per year. This finding illustrate that pulmonary hypertension in 
COPD progress slowly68. In our study, the distribution of pulmonary 
hypertension among mild, moderate, severe and very severe COPD were 33.3%, 
26.7%, 35.3% and 60% respectively. A recent small cohort reported that the 
frequencies of PH in mild, moderate, severe, and very severe COPD were 16.67 
%, 54.55 %, 60.00 %, and 83.33 %, respectively44. In another study, the 
frequency of PH was also found to be 25 %, 43 %, and 68 % in mild, moderate, 
and severe COPD, respectively62.Fayngersh V et al  studied the prevalence of 
PH in 105 stable COPD patient and found 60% (n=63) of patients with 
pulmonary hypertension. In their study, there was a significant association 
between FEV1 and pulmonary hypertension. COPD patients with PH had lower 
FEV1% predicted than the patients without pulmonary hypertension(51.8 ± 18.8 
vs. 62.7 ± 20.5%, P = 0.006)69 . In 2002, Scharf et al70 studied the hemodynamic 
characterization in patients with emphysema. They showed that COPD patients 
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with pulmonary hypertension had lower FEV1  compared to those without 
FEV1 which was statistically significant. Mammosser et al31 in their study  on 
COPD patients to assess pulmonary hypertension enlightened that subjects with 
pulmonary hypertension had lower FEV1 than those without pulmonary 
hypertension. The study by Higham et al60 in assessing the pulmonary artery 
pressure by echo found significant association between severity of COPD and 
pulmonary hypertension( r = -0.26, P = 0.05). Bishop et al71 used different non 
invasive techniques in predicting pulmonary artery pressure including 
echocardiography and found no correlation between severity of COPD and 
pulmonary hypertension.  Our study results were in partial agreement with the 
above mentioned studies. The prevalence of pulmonary hypertension in severe 
and very severe COPD were high compared to mild and moderate COPD.  In 
our study, the higher percentage of  pulmonary hypertension found in mild 
COPD patients(33.3%) might be due to less number of COPD patients in that 
group(n=3). None of them had severe pulmonary hypertension. Severe 
pulmonary hypertension in COPD  was  reported very rare. Thabut et al32  
reported only 1 to 3 % of severe PH among COPD patients. Gupta et al44 study 
had 17.65% of severe pulmonary hypertension among COPD patients.  We 
included  only  the stable COPD patients and those without other coexisting 
lung disease. The studies mentioned above excluded  the patients with other 
lung diseases but not those with exacerbation . 
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                     With respect to exercise capacity and pulmonary hypertension, in 
our study only 14% with pulmonary hypertension covered less than 350 meters, 
where as 86%(n=12) with PHT walked more than 350meters. Cuttica MJ et72  al 
in their study on non severe COPD patients, evaluated right heart changes in 
predicting exercise capacity and showed that mild pulmonary hypertension was 
a poor predictor of exercise capacity.  Boerrigter BG73 et al studied the 
ventilatory and cardiocirculatory exercise profiles in COPD and found that 
exercise capacity was  limited only in COPD patients with severe pulmonary 
hypertension.  Our study results were concurent with that of Cuttica et al and 
Boerrigter et al. 
                 By univariate analysis, statistically significant difference was 
observed for smoking pack years between COPD patients with pulmonary 
hypertension and COPD patients without pulmonary hypertension(Unadjusted 
odds ratio 1.03; 95% confidence interval 1.0 – 1.061; ‘P’ value = 0.05). 
However the relationship did not withstand adjustment with confounding 
factors like age, duration and severity of COPD(Adjusted odds ratio 1.021; 95% 
confidence interval 0.98 – 1.056; ‘P’ value = 0.20). COPD patients with 
pulmonary hypertension had lower BMI when compared to those without 
pulmonary hypertension which was statistically significant(19.82 ± 2.59 Vs 
22.31 ± 3.64, ‘P’ value = 0.030). On multiple logistic regression analysis, this 
relationship withstood adjustment with confounders like age, severity of COPD 
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and duration (adjusted odd’s ratio of  0.76,  95% confidence interval  0.59 – 
0.98, ‘P’ value of 0.04).  A study by Maurizio et al82 evaluated  COPD  patients 
of  specific  phenotype D and  pulmonary hypertension, showed significant 
correlation between pulmonary hypertension and BMI. Our study results were 
similar to the study by Maurizio et al. But, Kadam et al84  in their study with 30 
stable COPD patients compared  the severity of obstruction with pulmonary 
hypertension and osteoporosis. They found that  pulmonary hypertension 
correlated with FEV1 but not for BODE index(P = 0.88). Their study did not 
include all grades of severity. Similarly, Joppa et al85 studied 43 COPD patients 
of which 14 were females, to find the predictors of pulmonary hypertension. 
There was no statistical significant difference in BMI between the patients in 
pulmonary hypertension and  non pulmonary hypertension group ( 22.9 ± 6 vs 
24.6 ± 5.6, P = 0.352). Their study had 30% female population, 11% non 
smokers and none of them had biomass exposure and included COPD with 
different etiological profile. 
                         We found that patients with low BMI have 24% less chance for 
developing pulmonary hypertension. 
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                                               SUMMARY 
              Forty patients diagnosed as COPD without other lung disease and 
without primary cardiac disease had been included in the study. We evaluated 
the clinicophysiological characters like exercise capacity, lung function 
variables and correlated them with echocardiographic parameters like 
pulmonary hypertension, ventricular dimension and systolic, diastolic functions. 
All the participants were males with mean BMI of  21.44 ± 3.49 kg/m2. When 
socioeconomic status was considered, major proportion were above class 3.The 
mean  post bronchodilator FEV1and predicted FEV1 in our study population 
were 1.24 ± 0.49 Litres and 51.05 ± 16.09% respectively. The mean distance 
covered by our subjects during six minute walk test was 492 ± 90 metres. There 
was significant correlation between severity of COPD and exercise capacity 
assessed by six minute walk distance. We found a prevalence of 35% 
pulmonary hypertension among our study population. The prevalence of 
pulmonary hypertension increased with the severity of COPD. Left ventricle 
diastolic dysfunction was noted in 35% of the subjects. We divided the study 
population into two groups – COPD patients with pulmonary hypertension and 
COPD patients without pulmonary hypertension and compared variables 
between these two groups. By univariate analysis, statistically significant 
difference was observed for smoking pack years between COPD patients with 
pulmonary hypertension and COPD patients without pulmonary hypertension. 
However the relationship did not withstand adjustment with confounding 
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factors like age, duration and severity of COPD.COPD patients with pulmonary 
hypertension had lower BMI when compared to those without pulmonary 
hypertension which was statistically significant. On multiple logistic regression 
analysis, this relationship withstood adjustment with confounders like age, 
severity of COPD and duration (adjusted odd’s ratio of 0.76, 95% confidence 
interval 0.59 – 0.98, ‘P’ value of 0.04). We found that patients with low BMI 
have 24% less chance for developing pulmonary hypertension. 
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                                                CONCLUSION 
 
                         Our study showed that prevalence of pulmonary hypertension 
increased with severity of COPD. Severe pulmonary hypertension was not 
observed in our study with stable COPD patients. Right ventricle hypertrophy 
and diastolic dysfunction of left ventricle were the other common findings in 
COPD patients. Since cardiovascular disease is the major cause of morbidity 
and mortality in COPD, it is essential to evaluate the cardiac status at the time 
of initial diagnosis. The overall survival and quality of life can be improved by 
addressing this comorbidity. 
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                                            LIMITATION 
1. Forty samples were included in the study due to time constraints. 
2. Our study did not have female COPD patients. 
3. The sample distribution based on severity of COPD was unequal. 
4. Exact pulmonary pressure as measured by right heart catheterization 
cannot be obtained from echocardiography.  
5. Genetic factors known to be associated with pulmonary hypertension 
were not analysed in our study. 
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                                   RECOMMENDATION 
1. Studies with larger sample size and involving different ethnicity are 
needed. 
2. Uniform distribution of sample is needed to increase the credibility of the 
study. 
3. Genes  associated with pulmonary hypertension need to be incorporated 
in future studies. 
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                           MASTER CHART CODING SHEET 
OP NO – Outpatient number 
AGE in years 
BMI in Kg/m2 
Socio – Socioeconomic class(1- class 1) 
employ – Employment status(Y –Employed, N - Unemployed) 
Duration – Duration of disease(in years) 
exacerb –Number of  exacerbation in the previous year 
comorbi – Comorbidities( 0 – no comorbidities, 1 – systemic hypertension, 2 – Diabetes, 3 – CVA, 4 -GERD) 
Mmrc in grades 
FVC, FEV1 in litres 
FEV1% in percentage 
6MWD in metres 
SPO2 in percentage 
TR – significant jet(0- absent, 1- present) 
PH-(0- absent, 1- present) 
PAP in mmHg 
LVDD-(NO-absent, Y- present) 
LVEI in ratio 
EF in percentage 
OBSTRU- severity of COPD 
TAPSE, RVT,RVID,MPA,RPA,LPA, IVIDd, LVIDs, IVS,IVC in centimetres 
 
S.NO OP NO AGE BMI Socio employ pack yr Duration exacerb comorbi Mmrc FVC FEV1 FEV1% 6MWD
1 13047011 55 22.8 2 Y 50 2 0 4 1 3.34 2.16 88 580
2 13032651 64 16.5 5 N 30 5 1 0 3 2.28 0.82 35 370
3 13011190 61 20.08 4 Y 79 10 1 0 2 2.05 1.22 64 550
4 13087290 65 16.4 1 Y 96 3 1 0 2 1.91 0.87 48 580
5 13085849 71 15.4 4 N 70 3 0 2 2 1.65 0.9 51 400
6 13092026 50 19.3 3 N 37 3 1 4 3 2.88 1.21 46 450
7 12041260 74 27.1 2 N 52 2 0 0 1 2.09 1.2 55 640
8 3045869 56 26.8 3 N 27 15 1 3 2 2.14 0.81 49 430
9 14023282 62 18 3 Y 46 10 0 0 2 2.22 0.95 49 550
10 13045496 65 23 3 Y 47 2 1 2 2 2.7 2.5 62 360
11 10050186 54 25 2 Y 36 6 0 0 1 2.63 1.43 51 490
12 12072501 55 24.8 1 Y 40 4 1 4 2 1.81 1.15 47 570
13 14003763 65 24.9 1 Y 19 10 1 2 2 2.01 0.99 40 490
14 13053833 60 17.3 3 N 32 1 1 0 1 2.66 1.61 64 540
15 14029559 70 22 2 Y 47 5 0 1,2 2 2.88 1.07 59 540
16 14020105 40 21 2 Y 22 7 1 0 1 3.29 1.78 54 560
17 14016404 48 19.6 2 N 28 1 0 0 2 3.34 1.91 68 400
18 14033617 53 27.2 2 Y 29 4 0 2 1 2.25 1.48 55 470
19 6061352 64 23.3 2 Y 40 7 1 1 2 1.41 0.62 26 430
20 11013141 56 20 2 Y 35 6 0 0 1 2.11 1.19 58 570
21 14045546 71 28.4 2 N 72 4 0 1 2 2.54 1.64 69 430
22 14046148 55 17.2 3 Y 37 2 0 0 1 2.57 1.53 57 550
23 2045192 48 24 2 Y 22 10 1 0 2 3.58 2.08 73 570
24 7021257 64 23.3 1 Y 22 4 0 1,2 2 1.94 0.88 36 430
25 5052433 57 14.7 3 Y 40 5 2 1 3 1.04 0.35 30 410
26 8083168 71 21.2 4 N 110 6 2 0 2 1.27 0.49 22 320
27 13090284 80 20.1 1 Y 10 1 1 0 1 2.63 1.71 88 490
28 14048517 77 22.9 2 N 30 10 0 3 2 1.25 0.94 44 440
29 14049976 50 20 3 Y 10 10 2 0 2 1.92 1.21 56 490
30 11063165 58 19 2 Y 60 6 1 0 1 2.31 1.15 43 450
31 13073673 70 16.9 2 Y 67 5 2 0 2 1.22 0.64 29 350
32 12052274 67 23.4 2 Y 42 5 1 1,2 1 2.38 1.11 40 560
33 14026262 75 20.8 2 Y 75 10 3 0 3 1.13 0.51 29 330
34 4041711 60 25.5 2 N 10 10 1 2 1 2.81 1.66 64 640
35 12034934 42 19 2 Y 29 1 0 0 1 1.99 1.61 55 500
36 9082672 63 19.9 2 Y 46 10 1 0 2 1.92 0.87 31 560
37 11027745 61 24.4 2 Y 38 8 0 1 1 2.75 2.18 81 470
38 14061921 55 19.7 2 N 100 5 2 0 2 1.79 1.06 39 440
39 14037509 48 25.3 2 Y 20 2 1 0 1 1.86 1.01 37 690
40 9079223 66 21.5 3 Y 37 12 2 4 1 3.51 1.39 50 610
SPO2 TR PH PAP TAPSE RVT RVID LVDD MPA RPA LPA LVIDd LVIDs IVS LVEI EF VALVES IVC OBSTRU
99 0 0 0 1.9 0.77 1.92 NO 1.96 1.1 1.2 3.8 2.66 1.14 1.03 60 N 1.3 MILD
95 0 0 0 1.78 0.87 1.99 NO 3.04 2.64 2.3 4.5 3 1.31 1 63 N 1.7 SEV
97 1 1 45 2.4 0.5 1.99 NO 2.4 1.1 1.24 4.28 2.85 0.907 1.02 62 AS,AR 1.3 MOD
98 1 1 35 1.81 0.567 1.89 NO 1.37 1.39 4.17 2.66 1.02 1 66 N 1.04 SEV
98 1 1 37 1.86 0.68 1.99 NO 1.8 1.1 1.2 3.54 2.46 1.04 1.06 59 N 0.8 MOD
98 1 1 35 1.52 0.957 2.19 Y 2.06 1.19 1.46 3.99 2.76 1.24 1 59 N 1.5 SEV
96 1 0 24 1.79 0.731 3.18 NO 1.6 1.15 1.21 5.12 3.32 1.24 1.1 64 N 1.38 MOD
97 0 0 0 1.7 0.9 2.9 Y 1.3 0.9 1.14 4.03 2.77 1.09 1.2 60 AR 1.3 SEV
98 1 0 20 1.99 0.84 2.7 NO 1.28 1.09 0.8 4.2 2.8 1.2 1.22 63 AS,AR 1.4 SEV
97 1 1 40 1.9 0.6 2.66 NO 1.18 0.96 0.68 4.1 2.8 1.3 1.29 60 AS 1.15 MOD
98 1 0 25 1.96 0.581 2.86 NO 1.21 0.833 0.928 3.92 2.62 1.4 1.37 62 N 1.2 MOD
94 0 0 0 1.9 0.56 2.59 Y 1.11 1.04 1.02 4.78 3.32 0.84 1.02 58 N 0.8 SEV
98 0 0 0 1.97 0.57 2.5 NO 1.9 0.93 0.64 3.98 2.71 1.67 1.02 60 N 1.19 SEV
98 0 0 0 1.52 0.735 2.85 NO 1.92 0.7 0.93 4.41 2.98 1.21 0.97 60 N 1.04 MOD
98 1 1 45 1.79 0.66 3.24 Y 1.97 0.99 1.25 4.43 2.91 1.52 0.976 63 N 1.23 MOD
98 0 0 0 1.97 0.605 2.82 NO 1.24 1.04 0.69 4.03 2.67 1.41 1.01 63 N 1.15 MOD
97 0 0 0 1.97 0.605 2.03 NO 1.51 0.877 0.961 4.45 2.9 1.17 1.02 64 N 0.979 MOD
97 0 0 0 2.14 0.576 2.36 NO 1.5 1.02 1.07 4.9 3.17 1.27 1.1 64 N 1.31 MOD
98 1 1 49 2.12 0.922 3.34 NO 1.36 0.758 0.938 4.03 2.59 1.33 1.02 65 N 1.61 VERY
98 0 0 0 2.12 0.706 2.27 Y 1.24 0.698 0.77 4.03 2.67 0.857 1.12 63 N 0.922 MOD
97 0 0 0 1.99 0.73 2.98 NO 1.8 1.2 1.3 4.09 2.77 1.33 1.01 61 N 1.2 MOD
98 1 1 40 1.92 0.8 3.1 NO 1.4 1.1 1.3 4.45 2.68 1.56 1.1 70 N 1.24 MOD
98 0 0 0 2.19 0.55 2.47 NO 1.27 1.1 1.15 4.49 3.02 1.21 1.01 61 N 1.08 MOD
98 0 0 0 1.96 0.634 3 Y 1.62 1.02 1.22 3.92 2.69 2.15 1.05 59 N 1.08 SEV
98 1 0 25 1.97 0.735 2.53 NO 1.31 0.634 0.779 3.76 2.57 0.899 1.14 60 N 0.788 VERY
93 0 0 0 0.9 3.26 Y 1.84 0.893 1.1 3.09 2.19 1.07 1.2 57 AS 1.15 VERY
97 1 1 35 2.07 0.605 2.87 Y 1.6 0.97 1.01 3.98 2.52 1.11 1.02 67 AS 1.08 MILD
98 0 0 0 2.38 0.691 2.07 Y 1.81 0.824 0.991 3.68 2.57 1.21 1.01 58 N 1.19 SEV
98 1 1 30 2.37 0.872 2.91 NO 1.48 0.624 0.974 4.51 2.86 1.16 1.31 66 N 1.65 MOD
98 0 0 0 2.08 0.69 2.47 NO 1.4 0.8 1.1 4.51 2.96 1.02 1.01 63 N 1.23 SEV
94 1 1 35 1.92 0.572 2.7 NO 1.34 0.864 0.993 4.29 2.7 1.55 1 67 N 0.926 VERY
96 1 1 43 1.99 0.84 3.42 Y 1.27 1.03 1.11 4.05 2.59 1.46 1.01 66 N 1.69 SEV
97 1 1 45 2.17 0.449 1.8 NO 1.29 0.527 0.908 3.63 2.33 1.51 1.1 64 AS 1.06 VERY
98 0 0 0 1.51 0.678 2.76 Y 1.29 1.05 1.1 4.75 3.2 1.16 1 61 N 1.15 MOD
98 0 0 0 1.64 0.613 1.96 Y 1.23 0.67 0.726 3.68 2.49 1.35 1.1 61 N 1.11 MOD
99 1 0 15 2.08 0.605 2.2 NO 1.3 0.804 0.82 4.45 3.02 1.21 1.21 60 N 1.15 SEV
98 0 0 0 2.25 0.655 2.52 NO 1.53 0.758 0.773 3.43 2.42 1.35 1.15 57 N 1.2 MILD
95 1 1 37 2.07 0.519 2.03 NO 1.38 0.882 0.935 4.54 2.98 1.47 1 63 N 0.788 SEV
98 0 0 0 1.85 0.844 2.98 Y 1.34 1.01 1.03 4.6 2.86 1.11 1.02 68 N 1.08 SEV
97 1 0 21 2.14 0.454 2.23 Y 1.23 0.996 1.04 3.44 2.27 1.06 1.01 64 N 1.38 SEV
